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Loss	of	control	of	neuronal	excitability	underlies	conditions	such	as	seizure	and	
epilepsy,	where	 there	 is	excessive	or	synchronized	 firing	 in	 the	brain.	 	There	 is	
evidence	 that	 many	 epilepsies	 have	 a	 genetic	 basis	 that	 either	 causes	 or	
predisposes	individuals	to	seizures.		Many	animal	models	have	been	developed	to	
study	the	process	of	epileptogenesis,	or	the	process	by	which	the	brain	becomes	
epileptic.	Drosophila,	 in	particular,	has	been	increasingly	used	to	study	neuronal	
excitability	and	seizure	susceptibility	due	to	 its	 large	repertoire	of	genetic	 tools	
and	 collection	 of	 seizure‐sensitive	 and	paralytic	 behavioral	mutants.	 	However,	
while	many	of	these	seizure‐sensitive	mutants	show	similar	phenotypes,	many	of	
the	mutations	are	found	in	genes	that	have	no	clear	relationship	to	each	other.			In	
order	to	find	genes	that	enhance	excitability	and	possibly	find	pathways	that	link	
various	seizure	mutations,	we	have	performed	a	deficiency	screen	to	search	 for	
genes	 that	are	enhancers	of	seizure	susceptibility.	 	Bang‐sensitive	(BS)	mutants	
display	 a	 robust	 seizure	 phenotype	 in	 response	 to	 a	 mechanical	 or	 electrical	
stimulus	and	we	used	the	weakly	semi‐dominant	BS	mutant,	slamdance	(sda)	as	
the	 sensitized	background	 to	 screen	with	 a	 set	 of	 deficiency	mutants	 that	 span	
over	 chromosome	 3R.	 	 Through	 this	 screen,	 we	 found	 10	 candidate	 seizure	
enhancer	 genes,	 8	 of	 which	 have	 not	 been	 previously	 linked	 to	 a	 neuronal	
excitability	phenotype.		We	further	analyzed	pumilio	(pum),	one	of	the	enhancers	
 found	 in	 this	 screen.	 	pum	 encodes	 a	 translational	 repressor	 involved	 in	many	
processes	in	Drosophila	development,	from	larval	body	axis	patterning	to	roles	in	
nervous	 system	 development	 in	 later	 stages.	 	 To	 study	 the	 effect	 of	 pum	 on	
seizure	susceptibility,	we	have	used	behavioral	 testing	and	electrophysiology	as	
tools	to	determine	when	and	where	the	 loss	of	Pum	function	 leads	to	enhanced	
seizure	behavior.		We	have	found	that	Pum	functions	only	in	neurons,	especially	
cholinergic	 and	GABAergic	 neurons,	 to	 regulate	neuronal	 excitability	 and	 affect	
seizure	 susceptibility.	 	We	 further	 determined	 that	 Pum	expression	 is	 required	
both	 during	 the	 larval	 and	 pupal	 stages	 for	 proper	 regulation	 of	 neuronal	
excitability.	
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CHAPTER 1 
INTRODUCTION 
	
1.1		A	brief	overview	
The	regulation	of	the	information	flow	in	the	brain	through	the	neurons	and	their	
synapses	requires	a	careful	balance	of	excitability	and	inhibition.		Defects	in	this	
control	that	lead	to	excessive	excitability	or	lack	of	inhibition	can	cause	abnormal	
firing	 in	 the	brain,	 sometimes	 resulting	 in	 seizure,	 or	 even	epilepsy.	 	There	are	
numerous	 conditions	 that	 can	 lead	 to	 seizures,	 such	 as	 head	 injuries,	 medical	
conditions,	 stroke,	 and	 mutations	 in	 genes.	 	 The	 genetics	 behind	 seizure	 and	
epilepsy	 is	 of	 great	 interest	 because	 this	 helps	 us	 learn	 about	 how	 particular	
genes	are	important	in	the	proper	maintenance	of	activity	in	the	brain	from	early	
development	to	adulthood.		Through	studies	in	model	organisms,	much	has	been	
learned	about	how	seizures	and	epilepsy	can	develop.	
	
1.2		Advances	in	studying	the	genetic	basis	of	epilepsy	
A	seizure	is	an	event	in	which	there	is	either	excessive	or	synchronous	activity	in	
the	 brain.	 	 This	 activity	 can	manifest	 outwardly	 in	 a	 wide	 range	 of	 behaviors,	
from	 a	 short	 loss	 of	 awareness	 (absence	 seizure),	 to	 convulsions	 of	 the	 entire	
body	 (tonic‐clonic	 seizure).	 	The	seizures	can	be	 limited	 to	 specific	parts	of	 the	
brain	 in	 cases	 of	 partial	 seizure,	 or	 they	 can	 spread	 through	 the	 entire	 brain,	
which	is	known	as	a	generalized	seizure.		Epilepsy	occurs	when	seizures	become	
recurrent	 and	 unprovoked,	 and	 this	 condition	 affects	 1%	 of	 the	 population,	
making	it	a	prevalent	neurological	disorder	[1],	[2].			
	
Seizures	can	be	categorized	as	symptomatic	or	idiopathic.		Symptomatic	seizures	
are	those	where	the	cause	of	seizure	is	known,	such	as	from	head	trauma,	illness,	
drugs,	and	others.		In	idiopathic	seizures,	the	cause	of	the	seizure	is	not	apparent,	
and	often	these	are	assumed	to	have	an	underlying	genetic	basis	[3].					
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1.2.1	The	search	for	genes	underlying	epilepsy	
In	early	searches	for	genes	underlying	epilepsy,	Mendelian	genetics	was	used	to	
discover	mutations	 that	 caused	 epilepsies	 in	 families,	 using	 techniques	 such	 as	
pedigree	analysis	and	linkage	mapping.		In	many	of	these	cases,	the	mutated	gene	
turned	out	to	encode	defective	ion	channels	or	channelopathies,	such	as	SCN1A,	
which	 encodes	 a	 subunit	 of	 the	 voltage	 gated	 sodium	 channel,	 KCNQ2,	 which	
encodes	 a	 delayed	 rectifier	 	 potassium	 channel,	 and	GABRG2,	 which	 encodes	 a	
gamma‐aminobutyric	acid	(GABA)	receptor	subunit	(reviewed	in	[4–6]).			
	
More	recently,	newer	 techniques	have	been	used	 to	 identify	genes	 that	had	not	
previously	 been	 known	 to	 be	 involved	 in	 epilepsy	 and	 do	 not	 encode	 ion	
channels.		One	example	of	this	is	the	gene	STXBP1,	a	conserved	gene	also	known	
as	MUNC18	and	Sec1,	which	causes	early	infantile	epileptic	encephalopathy.		This	
gene	 was	 identified	 from	 a	 single	 patient	 using	 comparative	 genomic	
hybridization.	 	 Unlike	 the	 previously	 identified	 channelopathies,	 this	 gene	
product	 is	 involved	 in	 the	 release	 of	 synaptic	 vesicles	 [7].	 	 A	 genome‐wide	
association	study	was	also	performed	 in	order	 to	 find	candidate	epilepsy	genes	
among	 cases	 of	 partial‐onset	 epilepsy,	 though	 this	 did	 not	 produce	 any	 clear	
candidate	genes	[8].	 	Other	recent	studies	identified	potential	epilepsy	genes	by	
using	 an	 oligonucleotide	 assay	 to	 identify	 copy	 number	 variants	 in	 cases	 of	
idiopathic	epilepsy	[9].		It	is	suggested	that	as	the	field	of	epilepsy	genetics	moves	
forward,	 more	 modern	 techniques	 will	 be	 applied	 to	 discover	 new	 candidate	
genes	in	a	high‐throughput	manner	[6].	
	
There	are	a	variety	of	ways	to	affect	synaptic	transmission,	which	is	at	the	heart	
of	 neuronal	 excitability.	 	 These	 include	 regulation	 of	 second	 messengers,	
transcriptional	activation,	protein	trafficking,	phosphorylation,	RNA	editing,	and	
translational	control.		Defects	in	any	of	these	processes	can	result	in	a	number	of	
different	diseases	and	syndromes	affecting	the	nervous	system.		Often,	if	a	defect	
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results	in	an	increase	of	neuronal	excitability	or	lack	of	suppression	of	neuronal	
excitability,	this	can	result	in	seizure	or	epilepsy.	
	
1.2.3		Animal	models	of	epilepsy	
The	 search	 for	 genes	 underlying	 epilepsy	 is	 often	 limited	 by	 needing	 large	
numbers	of	people	affected	by	the	same	type	of	epilepsy	and	having	to	work	with	
epilepsies	 already	 in	 existence.	 	 Animal	 models	 offer	 many	 other	 methods	 of	
searching	 for	 novel	 genes	 underlying	 neuronal	 excitability,	 especially	 with	
respect	 to	 genes	 that	 may	 contribute	 to	 susceptibility	 to	 seizures	 though	 they	
cause	no	apparent	seizure	phenotype	on	their	own.	
		
Small	mammals,	 especially	mice	 and	 rats,	 have	 long	 been	 used	 as	 a	model	 for	
epileptogenesis	 and	 epilepsy,	 most	 commonly	 through	 either	 electrically	 or	
chemically	 induced	 seizures.	 	 One	 well‐known	 model	 is	 the	 classical	 kindling	
model,	where	 repeated	 seizures	 are	 induced	by	 chemical	 or	 electrical	 stimulus.	
This	 method	 added	 to	 knowledge	 about	 changes	 in	 behavior	 after	 recurrent	
seizures.	 	There	are	other	models	of	 recurrent	 spontaneous	seizures	 that	begin	
with	 exposure	 to	 convulsants	 such	 as	 pilocarpine	 or	 kainate.	 	 There	 have	 also	
been	 studies	 of	 genetic	 and	 transgenic	 mouse	 seizure	mutants	 that	 have	 been	
used	to	model	specific	types	of	epilepsy	(reviewed	in	[10],	[11]).			
	
More	 recently,	 zebrafish	 studies	 have	 made	 progress	 in	 epilepsy	 research.		
Zebrafish	 have	 been	 used	 in	 anti‐epileptic	 drug	 screening	 to	 test	 responses	 to	
chemically	 induced	 seizures	 while	 recording	 brain	 responses	 using	
electroencephalograms.	 	There	are	also	genetic	 zebrafish	epilepsy	models,	 such	
as	 one	 made	 by	 knocking	 down	 the	 voltage‐gated	 potassium	 channel	 KCNQ3	
using	morpholinos		(reviewed	in	[12]).	
	
	
 4 
Drosophila	is	another	model	organism	that	has	been	actively	involved	in	epilepsy	
research.		In	many	ways,	they	are	an	ideal	organism	for	particular	aspects	of	this	
field	of	study,	such	as	in	mutant	screens	and	anti‐epileptic	drug	screens.			
	
1.3		Drosophila	as	a	model	of	seizure	and	epilepsy	
The	strengths	of	Drosophila	as	a	genetic	model	organism	make	it	an	ideal	system	
to	 use	 for	 epilepsy	 studies.	 	 Flies	 exhibit	 a	 number	 of	 interesting	 behaviors,	
including	 various	 seizure	 and	 paralytic	 phenotypes.	 	 Their	 short	 lifespans	 and	
small	 size	 make	 it	 possible	 to	 screen	 large	 numbers	 of	 flies	 quickly.	 	 The	
availability	 of	 genetic	 tools	 also	 allow	 for	 in‐depth	 analysis	 of	 individual	 genes	
and	interactions	between	them.		Work	in	Drosophila	has	made	many	advances	in	
characterizing	seizure	mutants	and	developing	techniques	that	allow	us	to	learn	
about	 their	 behavior,	 and	 then	 use	 these	 tools	 to	 explore	 the	 genetic	 basis	 of	
neuronal	excitability	and	methods	of	seizure	suppression.	
	
1.3.1		Drosophila	bang‐sensitive	mutants	
Near	 the	 start	 of	 research	 into	 the	 study	 of	 neurogenetics	 in	Drosophila,	many	
behavioral	 mutants	 were	 collected	 in	 order	 to	 learn	 more	 about	 altered	
membrane	physiology,	often	 through	changes	 in	 ion	channel	 function.	 	 Some	of	
the	 earliest	 known	 behavioral	 mutants	 that	 displayed	 seizure	 or	 paralysis	
phenotypes	were	indeed	ion	channel	mutants.		For	example,	three	mutants	were	
discovered	 that	 had	 leg‐shaking	behavior	 upon	 exposure	 to	 ether.	 	 These	were	
named	Shaker	 (Sh),	ether‐a‐go‐go	 (eag),	 and	Hyperkinetic	 (Hk).	 	The	underlying	
cause	of	the	phenotype	was	discovered	to	be	defects	in	potassium	ion	channels.		
Likewise,	 three	 temperature‐sensitive	 paralytic	 mutants,	 temperature‐induced	
paralysis	 (tipE),	 no	 action	 potential	 (napts),	 and	 paralytic	 (para)	 had	 defects	 in	
sodium	ion	channels	(reviewed	in	[13]).			
	
Bang‐sensitive	 (BS)	mutants	have	an	even	more	dramatic	 seizure‐like	behavior	
compared	 to	 the	 leg‐shaking	 and	 temperature	 sensitive	 mutants.	 	 Though	
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phenotypically	 normal	 in	most	 circumstances,	 they	 respond	 to	 stimuli	 such	 as	
mechanical	 impact	 or	 electrical	 stimulus	 with	 a	 robust	 seizure	 and	 paralysis	
phenotype	[13–15].		To	date,	there	are	14	bang‐sensitive	mutants	that	represent	
12	different	 genes	 [16].	 	One	of	 the	 confusing	aspects	of	 these	BS	mutants	was	
that	 the	 genes	 underlying	 these	 mutations	 code	 for	 a	 wide	 variety	 of	 gene	
products	 that	do	not	have	obvious	 connections	despite	 their	 similar	behavioral	
phenotypes.	 	For	example,	 the	products	of	 the	genes	affected	 in	the	BS	mutants	
technical	 knockout	 (tko),	 kazachoc	 (kcc),	 and	 couch	 potato	 (cpo)	 are	 a	
mitochondrial	 ribosomal	 protein,	 citrate	 synthase,	 and	 RNA‐binding	 protein,	
respectively	[17–19].		easily	shocked	(eas)	is	a	robust	recessive	BS	mutant	that	is	
defective	 in	 an	 ethanolamine	 kinase,	 resulting	 in	 an	 altered	 membrane	
phosopholipid	 composition	 [20].	 	 slamdance	 (sda)	 mutants	 have	 a	 defect	 in	
aminopeptidase	 N,	 which	 leads	 to	 an	 increased	 persistent	 sodium	 current	 in	
motoneurons,	 which	 suggests	 an	 increased	 excitability	 of	 the	 motor	 system.		
Electrophysiological	 and	 pharmacological	 tests	 indicate	 that	 the	 sda	 seizure	
phenotype	may	arise	from	defects	 in	neural	development	[21],	[22].	 	One	of	the	
most	robust	and	difficult	to	suppress	BS	mutation	is	paralyticbangsenseless1	(parabss1)	
which	 has	 been	 essential	 in	 developing	 a	 Drosophila	 model	 for	 seizure	 and	
epilepsy	[23],	[24].	 	Though	this	mutant	was	used	as	a	model	for	seizure	in	flies	
for	many	years	due	to	its	tonic‐clonic‐like	seizures,	it	was	not	until	recently	that	
parabss1	 mutation	 was	 confirmed	 to	 be	 a	 gain‐of‐function	 allele	 of	 the	 sodium	
channel	gene	encoded	by	para.		This	gain‐of‐function	mutation	results	in	a	defect	
of	 sodium	 channel	 inactivation	 [25].	 	 It	 is	 also	 interesting	 to	 note	 that	 loss‐of‐
function	mutations	in	para	are	very	effective	seizure	suppressors	[24].	
	
The	 seizure	 behavior	 of	 BS	 mutants	 follows	 a	 stereotyped	 pattern	 for	 most	
members	of	this	group.		After	the	mechanical	or	electrical	stimulus,	the	flies	have	
a	brief	seizure	where	all	parts	of	their	body,	including	wings,	legs,	proboscis,	and	
abdomen,	contract	and	shake.		This	brief	seizure	lasts	only	a	few	seconds	and	is	
followed	 by	 a	 period	 of	 paralysis	 where	 the	 flies	 are	 unresponsive	 to	 any	
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mechanical	or	electrical	stimulus.	 	Finally,	the	flies	have	a	brief	recovery	seizure	
similar	 to	 the	 initial	 seizure	 [26].	 	 parabss1	 mutants	 deviate	 slightly	 from	 this	
pattern	 in	 that	 there	 is	 a	 tonic‐clonic	 phase	 in	 between	 the	 period	 of	 paralysis	
and	the	recovery	seizure	[25].		Heterozygous	BS	mutants	for	the	most	part	do	not	
show	 BS	 behavior,	 except	 in	 the	 case	 of	 sda	 and	 parabss1,	 which	 are	 semi‐
dominant.	 	 The	 penetrance	 of	 seizure	 is	 lowered	 greatly	 in	 sda	 heterozygotes,	
while	parabss1	heterozygotes	have	higher	penetrance.	 	If	seizure	is	initiated	after	
the	stimulus,	these	heterozygotes	show	typical	BS	seizures.		In	the	case	of	parabss1	
flies,	 this	 means	 that	 heterozygotes	 do	 not	 have	 a	 tonic‐clonic	 phase	 in	 their	
behavior	[25–27].			
	
While	the	BS	behavior	is	easily	observed	using	a	mechanical	impact,	this	is	an	all‐
or‐none	 behavior	 that	 can	 be	 only	 quantified	 by	 the	 penetrance	 of	 the	 BS	
phenotype,	 which	 is	 very	 high	 in	 homozygous	 BS	 mutants.	 In	 order	 to	 obtain	
more	quantitative	measurements	of	the	change	in	seizure	threshold	in	various	BS	
mutants,	 a	 method	 of	 delivering	 electrical	 stimuli	 directly	 to	 the	 brain	 and	
eliciting	 seizure	 through	 the	 giant	 fiber	 (GF)	 pathway,	which	 is	 responsible	 for	
the	fly	escape	response,	was	developed.		The	activation	of	the	GF	pathway	due	to	
the	 electrical	 stimulus	 caused	 trains	 of	 seizure‐like	 activity	 in	 the	 dorsal	
longitudinal	muscles	(DLM)	of	the	flight	muscles	in	BS	animals	[20].	 	During	the	
paralysis	phase	of	 the	seizure,	 there	was	a	corresponding	 failure	of	 the	DLM	to	
respond	to	any	stimulation	of	the	GF	pathway	[15].	Using	this	method,	the	seizure	
thresholds	 of	 various	 BS	 mutants	 were	 measured,	 allowing	 the	 mutants	 to	 be	
ranked	by	seizure	susceptibility.		Not	surprisingly,	parabss1	had	the	lowest	seizure	
threshold,	supporting	its	position	as	the	most	severe	BS	mutant	[23].		
	
1.3.2		Searching	for	suppressors	and	enhancers	of	seizure	in	Drosophila	
With	 the	 availability	 of	 behavioral	 and	 electrophysiological	 techniques	 to	
quantify	 the	 seizure	 susceptibility	 of	 BS	 mutants,	 screens	 for	 possible	 genetic	
suppressors	 and	 enhancers	 of	 the	 BS	 phenotype	 became	 an	 area	 of	 interest.		
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Analysis	of	other	mutations	that	have	the	ability	 to	suppress	or	enhance	the	BS	
phenotype	could	facilitate	the	discovery	of	mechanisms	or	pathways	underlying	
and	regulating	neuronal	excitability.	 	There	is	also	the	possibility	of	discovering	
novel	 targets	 for	 testing	 anti‐epileptic	 and	 anti‐convulsant	 drugs.	 	 In	 general,	
most	of	the	discovered	genes	have	been	suppressors	of	BS	mutations.	
	
Some	 of	 the	 first	 experiments	 in	 this	 area	 observed	 the	 effects	 on	 different	
seizure	and	paralysis	mutants	in	combination	with	each	other.	 	Therefore,	these	
tests	started	with	two	behavioral	mutants.	 	Several	of	the	temperature‐sensitive	
paralytic	 mutants,	 such	 as	 napts	 and	 para,	 were	 able	 to	 successfully	 suppress	
bang‐sensitive	seizures	[26],	[28].			
	
Often	 a	 reverse	 genetics	 approach	 was	 taken	 in	 order	 to	 find	 enhancers	 and	
suppressors	 of	 bang‐sensitivity.	 	Genes	known	 to	 affect	 neuronal	 excitability	 in	
other	 organisms	 are	 then	 tested	 in	 Drosophila	 to	 see	 their	 effects	 on	 seizure	
behavior.		One	example	of	this	is	the	study	of	shakB2.		Previous	work	showed	that	
mouse	 mutants	 of	 a	 specific	 connexin,	 or	 gap	 junction	 protein,	 had	 weakened	
epileptoform	 discharges	 in	 hippocampal	 slices	 [29].	 	 Because	 of	 this	 result,	
shakB2,	 a	Drosophila	 gap	 junction	 protein	mutant,	 was	 tested	with	 BS	mutants	
and	the	results	indicated	that	this	allele	is	able	to	suppress	or	partially	suppress	
seizures	in	many	BS	mutants	[30].	
	
Genetic	screens	for	suppressors	of	BS	mutants	have	also	been	performed.		Genes	
that	are	found	in	such	screens	are	ones	that	have	not	previously	been	implicated	
in	 seizure	 susceptibility.	 	 For	 example,	 in	 a	 screen	 for	 gain‐of‐function	 seizure	
suppressors	 of	 eas,	 the	 gene	 escargot	 (esg)	 was	 identified	 multiple	 times	 as	 a	
seizure	 suppressor,	 among	 several	 other	 genes.	 	 esg	 is	 particularly	 of	 interest	
because	it	 is	 involved	in	neural	development	and	is	able	to	suppress	seizures	in	
multiple	 BS	 mutants	 [31].	 	 In	 another	 suppressor	 screen	 using	 P	 element	
mutagenesis	 in	 the	 eas	 background,	 the	 gene	 topoisomerase	 I	 (top1JS)	 was	
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discovered	 to	 be	 a	 BS	 suppressor.	 	 This	 gene	 also	 had	 not	 been	 previously	
implicated	 in	 seizure	 susceptibility	 and	 is	 involved	 in	Drosophila	 	 development	
[32].	 	 Currently,	 there	 have	 been	 no	 large‐scale	 screens	 searching	 for	 novel	
enhancers	of	seizure	susceptibility	in	BS	mutants.	
	
1.3.3		Anti‐epileptic	drug	screening	in	Drosophila	
One	of	the	greatest	strengths	of	model	organisms	such	as	Drosophila	is	the	ability	
to	 screen	 through	 many	 flies	 relatively	 quickly	 and	 without	 using	 excessive	
resources,	 such	 as	 in	mutagenesis	 screens.	 	With	 the	 availability	of	 fly	mutants	
that	either	cause	seizure	behavior	or	can	suppress	seizure	behavior,	screening	for	
new	 anti‐epileptic	 drugs	 in	 Drosophila	 becomes	 possible.	 	 Discovery	 of	 anti‐
epileptic	 drugs	 affecting	 BS	 mutants	 can	 also	 help	 reveal	 the	 mechanisms	
underlying	the	bang‐sensitive	phenotype,	which	is	not	well	understood.			
	
Much	of	 the	 initial	drug	 testing	was	 to	confirm	that	 flies	are	able	 to	respond	to	
known	anti‐epileptic	drugs	in	order	to	support	Drosophila	as	a	seizure	model	for	
human	epilepsies.	 	Anti‐epileptic	drugs	that	successfully	suppressed	BS	seizures	
include	gabapentin,	phenytoin,	valproate,	and	potassium	bromide.		Though	these	
drugs	were	effective	suppressors,	other	drugs	 tested	were	not	able	 to	suppress	
BS	 seizures	 [30],	 [33–36].	 	 Some	 of	 the	 effects	 of	 these	 drugs	 include	 faster	
recovery	from	paralysis,	or	suppression	of	tonic‐clonic	behavior	in	parabss1	[32].	
	
Potentially	 novel	 anti‐epileptic	 drugs	 have	 been	 suggested	 through	 testing	
inhibitors	of	top1JS,	a	previously	mentioned	suppressor	of	BS	seizures.		Drugs	that	
are	known	inhibitors	of	top1JS	were	tested	on	BS	mutants.	 	Some	of	these	drugs,	
such	as	camptothecin	and	apigenin,	were	able	to	suppress	BS	behavior	[32],	[35].		
This	 study	 represents	 the	 first	 example	 of	 discovery	 of	 potential	 anti‐epileptic	
drugs	through	Drosophila	BS	mutants.	
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1.4		Perspectives	
In	this	chapter,	the	genetics	behind	epilepsy	and	current	work	on	Drosophila	as	a	
model	 for	 epilepsy	 were	 reviewed.	 	 While	 many	 aspects	 of	Drosophila	 seizure	
susceptibility	have	been	studied,	such	as	the	behavior	of	bang‐sensitive	mutants,	
the	 genes	 underlying	 these	 behaviors,	 and	 the	 ability	 of	 anti‐epileptic	 drugs	 to	
suppress	 BS	 behavior,	 one	 area	where	 there	 has	 not	 been	much	 study	 are	 the	
genes	 responsible	 for	 seizure	 susceptibility,	 which	 can	 cause	 genetic	
predisposition	for	eventual	epileptogenesis.		In	chapter	2,	a	screen	for	enhancers	
of	the	BS	mutant	sda	is	described,	along	with	eleven	candidate	genes	that	may	be	
enhancers	 of	 seizure	 susceptibility.	 In	 chapter	 3,	 analysis	 of	 a	 gene,	 pumilio,	
which	was	found	through	this	screen	is	described.		This	work	is	then	summarized	
and	 discussed	 in	 chapter	 4.	 	 Appendix	 A	 summarizes	 the	 results	 of	 the	
preliminary	 deficiency	 screen	 that	 took	 place	 prior	 to	 the	 screen	 described	 in	
chapter	2.		Supplementary	material	for	chapter	2	can	be	found	in	Appendix	B,	and	
supplementary	material	for	chapter	3	is	in	Appendix	C.	
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CHAPTER 2 
DEFICIENCY SCREEN FOR ENHANCERS OF THE BANG-SENSITIVE 
MUTANT SLAMDANCE 
 
2.1  Abstract 
Neuronal	 excitability	 is	 a	 key	 factor	underlying	 the	 causes	of	disorders	 such	as	
seizures	and	epilepsy	and	is	greatly	influenced	by	genetics.		Drosophila	is	a	useful	
system	to	study	neuronal	excitability	and	seizure	susceptibility	due	to	the	 large	
library	of	seizure	and	paralytic	mutations	available,	as	well	as	the	ability	to	use	
high	throughput	genetic	screening	to	look	for	new	mutations.		I	am	interested	in	
finding	 genes	 that	 enhance	 neuronal	 excitability	 in	 flies	 using	 a	 sensitized	
seizure‐susceptible	 background.	 	 Bang‐sensitive	 (BS)	 mutants,	 in	 particular,	
display	a	robust	seizure	phenotype	after	a	mechanical	stimulus,	and	a	subset	of	
these	 mutants	 are	 semi‐dominant	 and	 the	 seizure	 phenotype	 is	 only	 partially	
penetrant	 in	 heterozygous	 animals,	 allowing	 us	 to	 screen	 for	 enhancers	 that	
increase	 the	 severity	 or	 penetrance	 of	 the	 phenotype.	 	 Using	 the	 BS	 mutant	
slamdance	(sda),	I	performed	a	deficiency	screen	with	the	Exelixis	3R	deficiency	
kit,	 looking	 for	 deficiencies	 that	 increased	 the	 penetrance	 of	 seizure	
susceptibility.		After	identifying	deficiencies	that	enhanced	BS	seizure	penetrance	
when	crossed	to	sda,	I	followed	up	with	crosses	to	other	deficiencies	and	alleles	
of	genes	within	the	deficiency	to	identify	candidate	BS	enhancer	genes.		Using	this	
method,	 I	was	able	to	 find	10	genes	with	known	functions	that	enhance	seizure	
susceptibility,	 8	 of	 which	 have	 not	 previously	 been	 described	 to	 cause	 this	
phenotype.	
 
2.2  Introduction 
Epilepsy,	 a	 seizure	 disorder	 characterized	 by	multiple	 unprovoked	 seizures,	 is	
extremely	prevalent	 in	 the	world	 today.	 	 It	affects	1%	of	 the	overall	population	
and	 is	 experienced	 by	 3%	 of	 the	 population	 at	 some	 point	 in	 their	 lives	 [1].		
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Because	 epilepsy	 is	 so	 widespread,	 and	 affects	 all	 age	 groups,	 research	 for	
diagnostics	and	treatment	are	a	high	priority.		While	advances	have	been	made	in	
these	areas	for	some	epilepsies,	knowledge	in	the	area	of	epileptogenesis,	or	the	
process	by	which	the	brain	becomes	epileptic,	is	far	from	complete.		Epilepsy	can	
be	caused	by	injury	or	illness,	but	this	cannot	account	for	all	epilepsies.		In	these	
other	cases,	epilepsy	is	likely	to	be	due	to	genetic	causes.		While	pedigree	studies	
of	families	with	a	high	incidence	of	epilepsy	have	identified	dominant	mutations	
in	genes	that	underlie	epilepsies	with	a	genetic	basis,	they	can	only	explain	a	very	
small	 percentage	 of	 these	 genetically‐based	 epilepsies.	 	 Known	 epilepsy‐
associated	genes	 that	encode	 ion	channels	 in	neurons,	where	mutations	 lead	 to	
channelopathies,	 can	 only	 account	 for	 less	 than	1%	of	 all	 epilepsies	 [2].	 	 Other	
genes	associated	with	epilepsy	are	involved	in	very	diverse	biological	processes,	
some	of	which	previously	had	no	connection	to	epilepsy	or	neuronal	excitability	
[3].					
	
In	 order	 to	 obtain	 a	 better	 understanding	 of	 known	 epilepsy	 genes,	 as	well	 as	
discover	 new	 ones,	 we	 need	 to	 turn	 to	 model	 systems.	 	 Animal	 models,	 from	
insects	 to	primates,	have	been	useful	 in	 learning	about	epileptogenesis,	 such	as	
through	mouse	models	of	electrical	kindling	or	chemically	induced	seizures	using	
convulsants	 [2],	 [4].	 	 Certain	models	 are	 also	 important	 for	 anti‐epileptic	 drug	
screening	 [5].	 	 However,	 one	 of	 the	 great	 strengths	 of	model	 organisms	 is	 the	
greater	ease	in	discovering	mutations	in	genes	that	underlie	the	predisposition	to	
seizure	or	epilepsy.			
		
Drosophila	in	particular	are	suited	for	high	throughput	genetic	screening	and	for	
determining	 gene	 function	 in	 vivo.	 	 Their	 short	 lifespans	 and	 a	 more	 compact	
genome	 with	 single	 copies	 of	 genes	 that	 may	 be	 found	 as	 multiples	 in	 a	
mammalian	 genome	 are	 two	 important	 features	 of	 this	 model	 system.	 	 The	
availability	of	well‐developed	genetic	tools	is	also	advantageous	for	screening	or	
genetic	 manipulation.	 	 While	 this	 system	 has	 been	 essential	 in	 studying	 many	
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different	 biological	 processes,	 one	 concern	 may	 be	 that	 flies	 are	 not	 the	 ideal	
animal	 system	 to	be	 studying	 a	behavior	 such	 as	 epilepsy.	 	However,	 there	 are	
many	similarities	between	flies	and	mammals	at	the	cellular	level,	such	as	in	ion	
channels	and	membrane	properties	involved	in	synaptic	transmission.		There	has	
been	recent	work	showing	that	Drosophila	can	be	used	as	a	model	for	seizure	in	a	
number	of	different	ways,	including	behavioral		and	electrophysiological	analysis	
of	 existing	 seizure	 mutants,	 screening	 for	 genetic	 seizure	 suppressors,	 and	
searching	 for	 seizure‐suppressing	 chemicals	 and	 drugs	 [6].	 	 For	 example,	
electrical	stimuli	to	fly	brains	can	induce	seizure‐like	behavior	[7],	[8].		Also,	anti‐
epileptic	 drugs	 such	 as	 valproate	 [9],	 phenytoin,	 gabapentin	 [10],	 potassium	
bromide	 [11],	 and	 levetiracetam	 (Ronald	 Hoy	 and	 David	 Deitcher,	 personal	
communication)	have	been	found	to	suppress	seizure	behaviors	in	flies.	
	
Drosophila	 seizure	 mutants	 have	 altered	 neuronal	 excitability	 compared	 to	
normal	 flies	 and	 exist	 in	 several	 main	 categories:	 leg‐shakers,	 temperature	
sensitives,	and	bang‐sensitives	[12].	 	The	Drosophila	bang‐sensitive	(BS)	mutant	
class	 contains	 14	 alleles	 of	 12	 genes	 [6].	 	 Some	 of	 these	 mutants,	 such	 as	
paralyticbangsenseless1	 (parabss1)	 and	 slamdance	 (sda),	 are	 semi‐dominant	 in	 the	
heterozygous	 state	 [7].	 	parabss1	 is	 considered	 to	 be	 one	 of	 the	 strongest	 bang‐
sensitive	 mutants,	 and	 the	 electrical	 activity	 in	 the	 brain	 during	 the	 seizure	
behavior	is	likened	to	tonic‐clonic	seizures.	 	It	 is	known	to	be	a	gain‐of‐function	
allele	 of	 the	 paralytic	 voltage‐gated	 Na+	 channel	 [13].	 	 Another	 bang‐sensitive	
mutant,	 sda,	 has	a	weaker	 seizure	phenotype	 than	parabss1	 [7].	 	The	 seizures	 in	
this	 mutant	 are	 due	 to	 a	 mutation	 in	 the	 Drosophila	 homolog	 of	 human	
aminopeptidase	 N,	 which	 causes	 an	 increase	 in	 persistent	 Na+	 current	 and	
reduced	Ca2+	current	[14],	[15].	 	The	semi‐dominant	phenotype	in	heterozygous	
parabss1	and	sda	manifests	as	a	much	lower	penetrance	of	the	seizure	phenotype,	
meaning	a	smaller	percentage	of	heterozygous	flies	have	seizures	in	response	to	
the	stimulus	than	homozygous	flies	[7].	
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I	wished	 to	 use	 this	 knowledge	 of	 bang‐sensitive	mutants	 to	 learn	more	 about	
genes	that	may	be	involved	in	seizure	susceptibility	when	mutated.		My	rationale	
for	this	 is	that	there	are	many	genes	that	may	have	not	yet	been	found	because	
their	 effect	on	bang‐sensitivity	 is	not	apparent	as	a	 single	mutation.	 	 Similar	 to	
how	a	variety	of	mutations	can	provide	a	genetic	disposition	toward	seizure	and	
epilepsy	in	people,	yet	seizures	do	not	manifest	unless	another	injury	is	present,	
there	may	be	a	number	of	genes	in	Drosophila	that	will	reveal	enhanced	neuronal	
excitability	 only	 in	 the	 presence	 of	 another	 mutation	 providing	 the	 seizure‐
susceptible	 background.	 	 	 Much	 work	 has	 been	 done	 using	 bang‐sensitive	
behavior	to	identify	seizure	suppressors	[16–18],	and	these	studies	usually	used	
the	homozygous	BS	mutation	 in	order	 to	screen	 for	suppressors.	 	To	screen	 for	
enhancers	 of	 BS	 seizures,	 I	 used	 the	 low	 penetrance	 of	 the	 heterozygous	 BS	
mutant	as	a	sensitized	background	to	find	alleles	of	genes	that	may	enhance	this	
penetrance.	 	The	design	of	this	screen	is	modeled	on	the	sevenless	screen	which	
was	used	to	discover	components	of	the	receptor	tyrosine	kinase	pathway	[19].		
The	 rationale	 behind	 this	 particular	 screen	 was	 that	 a	 reduction	 of	 50%	 of	 a	
pathway	 component	 can	 result	 in	 enhancement	 or	 suppression	 of	 the	 mutant	
phenotype.		Although	this	was	a	very	successful	screen,	one	of	the	drawbacks	was	
the	time	and	effort	needed	to	map	the	mutations	created	by	EMS.		With	updated	
genetic	 tools	 available	 for	Drosophila	 research,	 such	 as	 libraries	 of	 deficiencies	
with	 carefully	 documented	 endpoints,	 as	 well	 as	 thousands	 of	 transposon	
insertion	 mutants	 and	 RNAi	 lines,	 screening	 and	 mapping	 can	 be	 done	 much	
more	efficiently.		In	order	to	understand	more	about	genes	that	may	affect	bang‐
sensitivity	 directly	 as	 well	 as	 increase	 our	 knowledge	 base	 of	 genes	 that	 can	
enhance	neuronal	 excitability	 as	a	heterozygous	mutation,	 I	 have	 conducted	an	
enhancer	screen	 in	a	heterozygous	bang‐sensitive	background	 to	 identify	genes	
that,	 when	mutated,	 increase	 the	 strength	 or	 penetrance	 of	 the	 bang‐sensitive	
phenotype.	
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2.3 Methods 
Fly	stocks	
All	 flies	were	 raised	 on	 standard	 yeast	 and	 glucose	media	 at	 25°C.	 	 I	 used	 the	
Exelixis	3R	deficiency	kit	 (Bloomington	Stock	Center)	 for	 the	deficiency	 screen.		
Several	seizure	mutants,	specifically	of	the	bang‐sensitive	class,	were	used	in	the	
heterozygous	 state	 as	 sensitized	 backgrounds	 for	 the	 screen.	 	 The	 three	 bang‐
sensitive	 lines	 I	used	 include	slamdance	 (sda),	paralyticbangsenseless1	 (parabss1),	and	
easily	shocked	 (eas),	and	were	a	gift	 from	Ronald	Hoy.	 	For	behavioral	controls,	
we	 crossed	 these	 bang‐sensitive	 lines	 to	w1118	 (#5905	 and	 #6326).	 	 Follow‐up	
crosses	to	the	screen	involved	deficiencies,	transposon	insertion	stocks,	or	RNAi	
stocks	 available	 from	 the	 Bloomington	 Stock	 Center.	 	 A	 complete	 list	 of	 stocks	
used	is	found	in	Table	B.1,	and	organized	in	greater	detail	in	Tables	B.5,	B.6,	and	
B.7.	 	 In	cases	of	RNAi	stocks,	we	targeted	knockdown	 in	all	neurons	using	elav‐
GAL4	(#458	and	#8763)	recombined	with	sda.			
	
Seizure	behavior	induction	in	adults	
To	 test	 for	 bang‐sensitive	 paralysis,	 we	 performed	 testing	 similar	 to	 that	
previously	described	[7].		Briefly,	adult	flies	were	collected	1‐4	days	post	eclosion	
and	 anaesthetized	with	 CO2.	 	 Approximately	 20	 flies	were	 placed	 in	 food	 vials	
with	cotton	plugs	and	allowed	to	recover	for	at	least	12	hours	before	testing	for	
penetrance	of	bang‐sensitive	paralysis.		For	seizure	and	paralysis	induction,	vials	
were	 turned	upside	down	and	given	a	mechanical	vortex	stimulus	at	maximum	
speed	for	10	seconds	(Vortex	Genie	2,	VWR	Scientific).		Immediately,	the	number	
of	flies	that	were	paralyzed	or	seizing	were	counted.		Each	vial	was	monitored	for	
a	minute	for	recovery	of	flies	from	paralysis	in	order	to	exclude	flies	that	did	not	
recover	from	seizure.		All	behavior	testing	was	done	during	the	same	time	of	day,	
and	approximately	60	flies	of	each	genotype	were	tested.		Data	was	represented	
as	 either	 a	 percentage	 of	 flies	 showing	 paralysis	 after	 vortexing	 over	 the	 total	
number	of	flies	tested,	or	as	a	fold	change	of	(%	of	flies	paralyzed)/(%	of	control		
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Figure	2.1.		Schematic	of	deficiency	screen	for	enhancers	of	sda	
	
Bang‐sensitive	slamdance	(sda)	virgins	were	crossed	to	males	of	the	Exelixis	3R	
deficiency	 kit	 and	 F1	 progeny	 were	 tested	 for	 seizure	 susceptibility	 upon	
vortexing.	 	 Those	 lines	 that	 had	 a	 large	 increase	 in	 paralysis	 after	 vortexing	
compared	 to	 sda/+	 were	 analyzed	 for	 genes	 of	 interest	 or	 other	 overlapping	
deficiencies.	 	Further	crosses	testing	overlapping	deficiencies	or	alleles	of	genes	
of	interest	were	done	to	determine	putative	enhancers	of	bang‐sensitivity.	
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flies	paralyzed).	 	Controls	were	either	sda/+	(to	compare	to	all	cases	except	 for	
RNAi	stocks)	or	elav‐GAL4/+;	sda/+	(to	compare	to	RNAi	stocks)	flies.	
	
Genetics	
The	 deficiency	 screen	 for	 enhancers	 of	 bang‐sensitivity	 was	 done	 as	 follows:		
slamdance	 virgins	 were	 crossed	 to	 males	 of	 the	 Exelixis	 Df	 3R	 Kit	 and	 the	 F1	
progeny	were	 collected,	 sorted,	 and	 tested	 for	 the	penetrance	of	bang‐sensitive	
paralysis	as	described	above.		Deficiencies	that	caused	an	approximately	twofold	
or	 greater	 increase	 in	 seizure	 penetrance	 compared	 to	 sda/+	 controls	 were	
considered	to	contain	a	possible	enhancer(s).	 	Since	there	are	available	data	for	
the	endpoints	of	each	Exelixis	deficiency,	the	available	data	were	used	to	identify	
overlapping	deficiencies	and	transposon	insertions	or	RNAi	lines	for	genes	within	
the	Exelixis	deficiencies.	 	These	lines	were	tested	for	bang‐sensitive	paralysis	as	
described	above.			
 
2.4 Results 
2.4.1	Deficiency	screening	for	enhancers	of	bang‐sensitivity	penetrance	
Within	 the	 category	 of	 seizure‐susceptible	 Drosophila	 mutants,	 bang‐sensitive	
flies	 have	 a	 particularly	 robust	 phenotype	 in	 that	 they	 display	 a	 stereotyped	
seizure‐paralysis‐seizure	 phenotype	 upon	 being	 given	 a	 stimulus,	 such	 as	 a	
mechanical	impact	[20].		Heterozygotes	of	some	bang‐sensitive	mutants,	such	as	
sda	 and	parabss1	 are	 semi‐dominant	and	display	 a	 shorter	 seizure	and	paralysis	
phenotype	 at	 a	 lower	 penetrance	 than	 the	 homozygous	 mutant	 [7].	 	 We	 used	
these	 characteristics	 of	 heterozygous	 bang‐sensitive	 flies	 as	 a	 sensitized	
background	 in	 which	 to	 screen	 for	 genes	 that	 may	 be	 involved	 in	 neuronal	
excitability.	 	 Specifically,	 we	 crossed	 slamdance	 (sda)	 virgins	 to	 males	 of	 the	
Exelixis	 3R	 Deficiency	 Kit	 and	 tested	 progeny	 from	 these	 crosses	 for	 bang‐
sensitivity,	 focusing	 on	 the	 number	 of	 flies	 displaying	 paralysis	 after	 vortexing	
(Figure	 2.1).	 	 Our	 goal	 was	 to	 identify	 genes	 that	 showed	 non‐allelic	
noncomplementation	with	sda,	as	this	may	uncover	interactors	with	sda	or	other	
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Table	2.1	
3R	Exelixis	deficiencies	that	enhance	bang‐sensitivity	in	sda	
	
Exelixis	
Number	
Stock	
Number	
%	
paralyzed
Fold	
increase
Number	
tested	
#	of	genes	
deleted	
"Enhancers"	 		 		 		 		 		
Df(3R)Exel6150		 7629	 23.1	 3.8	 74	 35	
Df(3R)Exel6151		 7630	 63.3	 10.4	 120	 2	
Df(3R)Exel6154		 7633	 50.8	 8.3	 59	 11	
Df(3R)Exel6161		 7640	 23.9	 3.9	 71	 15	
Df(3R)Exel6165		 7644	 60.0	 9.8	 60	 40	
Df(3R)Exel6178		 7657	 21.7	 3.6	 60	 48	
Df(3R)Exel6196		 7675	 43.3	 7.1	 60	 20	
Df(3R)Exel6270		 7737	 71.7	 11.7	 60	 23	
Df(3R)Exel7379		 7919	 36.5	 6.0	 63	 14	
Df(3R)Exel7317		 7932	 40.4	 6.6	 52	 17	
Df(3R)Exel7305		 7956	 35.0	 5.7	 60	 16	
Df(3R)Exel8157		 7973	 32.4	 5.3	 71	 9	
Df(3R)Exel7328		 7983	 23.3	 3.8	 60	 17	
Df(3R)Exel9013		 7991	 23.3	 3.8	 60	 15	
Df(3R)Exel9025		 7995	 23.3	 3.8	 60	 3	
Control	 		 		 		 		 		
w1118	 5905	 6.1	 	1	 180	 1	
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genes	that	generally	affect	the	BS	phenotype.		The	sda	background	was	used	over	
other	 bang‐sensitive	 lines	 used	 because	 very	 few	 of	 the	 heterozygous	 sda	 flies	
show	 a	 bang‐sensitive	 phenotype,	 while	 other	 bang‐sensitives	 such	 as	 parabss1	
have	much	higher	penetrance	in	the	heterozygous	state	while	eas	heterozygotes	
are	essentially	wild‐type	in	behavior	(data	not	shown).	
	
The	Exelixis	3R	Deficiency	Kit	covers	approximately	65%	of	chromosome	3R	over	
138	 deletion	 lines	 [21]	 and	 we	 began	 the	 screening	 process	 with	 this	 set	 of	
stocks.	 	 After	 crossing	 the	 deletion	 lines	 of	 this	 kit	 to	 sda	 and	 behavior	 testing	
each	set	of	progeny	(A	complete	list	of	all	stocks	tested	and	behavioral	results	can	
be	found	in	Table	B.2),	we	discovered	19	deficiencies	that,	when	crossed	to	sda,	
caused	greater	than	20%	of	the	F1	progeny	to	seize	upon	vortexing	(Table	2.1).		
Paralysis	 of	 20%	 of	 the	 flies	 tested	 represented	 a	 3.8	 times	 fold	 increase	 in	
paralysis	 compared	 to	 the	 sda/+	 control.	 	 Four	 of	 the	 19	 deficiencies	 were	
removed	 from	 the	 list	 since	 other	 deficiencies	 that	 were	 not	 enhancers	
completely	 overlapped	 these	 four,	 leaving	 15	 deficiencies	 containing	 potential	
enhancers	of	the	BS	phenotype.	
		
We	investigated	the	specificity	of	the	enhancement	of	seizure	susceptibility	to	the	
sda	background	by	crossing	each	of	the	fifteen	Exelixis	deficiencies	to	two	other	
bang‐sensitive	 lines,	 parabss1	 and	 eas.	 	 We	 hypothesized	 that	 some	 of	 these	
deficiencies	would	cause	enhancement	of	bang‐sensitivity	only	in	sda,	possibly	as	
part	 of	 a	 sda‐specific	 pathway,	 or	 alternatively	 may	 be	 a	 general	 enhancer	 of	
neuronal	excitability	to	several	bang‐sensitive	lines.		The	F1	progeny	from	these	
crosses	were	tested	as	described	for	sda,	though	only	females	were	tested	as	both	
parabss1	and	eas	are	X‐linked.	 	For	parabss1,	 four	of	the	fifteen	sets	of	F1	progeny	
resulted	 in	 seizure	 susceptibility	 relatively	 unchanged	 from	 that	 of	 control	
parabss1/+	 flies,	while	 the	other	 lines	had	an	 increase	 in	 flies	 showing	paralysis	
(Figure	2.2	B,	Table	B.3).		The	maximum	fold	change	of	these	tested	flies	is	lower	
than	that	observed	with	sda	(2.6‐fold	for	parabss1	compared	to	11.7‐fold	for	sda)			
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Figure	 2.2	 	 Seizure	 penetrance	 enhancement	 by	 Exelixis	 deficiencies	 in	 three	
bang‐sensitive	 backgrounds.	 	 (A)	 	 Fold	 change	 in	 paralysis	 in	 a	 slamdance	
background,	(B)	in	a	parabss1	background,	and	(C)	percent	paralyzed	in	an	easily	
shocked	background.		N≥40	for	each	cross.	
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C		eas	
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due	 to	 the	 higher	 penetrance	 of	 bang‐sensitivity	 in	 the	 parabss1/+	 background.		
eas,	on	the	other	hand,	 is	a	recessive	mutation	and	eas/+	females	are	not	bang‐
sensitive.	 	 Crossing	 eas	 to	 the	 18	 deficiencies	 produced	 no	 increase	 in	 bang‐
sensitivity	 except	 for	 a	 very	 few	 flies	 showing	 seizure	 behavior	 in	 two	 lines,	
Exel6151	(4/52)	and	Exel6270	(1/89),	which	were	the	strongest	two	enhancers	
for	sda	(Figure	2.2	C,	Table	B.4).	
	
2.4.2	Searching	for	genes	involved	in	enhancing	neuronal	excitability	
The	Exelixis	 deficiency	 library	 is	 suited	 for	 enhancer	 and	 suppressor	 screening	
due	 to	 each	 deficiency	 having	 well‐documented	 breakpoints	 and	 lists	 of	 genes	
deleted	within	the	deficiency	[21].		Once	we	determined	the	eighteen	deficiencies	
that	 enhanced	 bang‐sensitivity,	 we	 followed	 up	 first	 by	 searching	 for	 existing	
deficiencies	 that	 overlap	 the	 Exelixis	 deficiencies	 in	 order	 to	 narrow	down	 the	
window	of	candidate	genes.		These	follow‐up	deficiency	tests	are	summarized	in	
Figure	 B.1	 and	 Table	 B.5,	 though	 some	 of	 the	 Exelixis	 deficiencies	 do	 not	
currently	have	any	overlapping	deficiency	lines	available	for	testing.			
	
Following	this	step,	we	searched	for	existing	alleles	of	candidate	genes	within	the	
Exelixis	deficiencies	 to	 test	with	 sda.	 	We	 focused	on	genes	highly	expressed	 in	
the	brain	and	the	nervous	system	relative	to	 the	rest	of	 the	expression	pattern,	
either	in	larval	or	adult	stages.		These	genes	would	be	the	most	likely	candidates	
for	 direct	 involvement	 in	 neuronal	 excitability	 instead	 of	 resulting	 indirectly	
through	 other	 defects.	 	 We	 preferentially	 selected	 available	 null	 alleles	 of	 the	
candidate	 genes	 as	 they	 would	 be	 most	 similar	 to	 a	 deletion,	 though	 in	 some	
cases	only	hypomorph	alleles	were	available.	 	These	alleles	were	crossed	to	sda	
and	tested	for	bang‐sensitivity,	summarized	in	Figure	2.3	and	Table	B.6.		
	
For	 some	candidate	genes,	 instead	of	mutant	alleles,	we	obtained	RNAi	 lines	 to	
test	 the	 effect	 of	 knockdown	 of	 the	 gene	 on	 bang‐sensitivity.	 	 Since	 we	 were	
searching	for	candidate	genes	highly	expressed	in	the	nervous	system,	we	tested		
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Figure	2.3	 	 Effects	 of	 transposon	 insertion	 alleles	 in	 enhancing	bang‐sensitivity	
penetrance.	 	 P‐element	 insertion	 alleles	 of	 potential	 bang‐sensitive	 enhancer	
were	crossed	to	sda	and	progeny	were	vortex	tested.		N	≥	60	flies	per	gene,	except	
Akt	(N=20),	CG10324(N=34),	and	CG5903	(N=20).	
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these	 RNAi	 lines	 by	 crossing	 males	 to	 elav‐GAL4;	 sda	 females	 to	 cause	
panneuronal	knockdown	of	the	gene.	 	We	tested	the	F1	progeny	using	the	same	
behavioral	protocol	as	in	the	screen	and	used	elav‐GAL4/+;	sda/+	as	a	behavioral	
control	 (Figure	 2.4,	 Table	 B.7).	 	 In	 general,	 crosses	 with	 an	 elav‐GAL4;	 sda	
background	 tended	 to	 have	 lower	 seizure	 penetrance	 than	 crosses	 in	 a	 sda	
background	
	
A	 summary	 of	 potential	 enhancer	 genes	 for	 sda	 is	 provided	 in	 Table	 2.2	 and	 a	
more	detailed	table	summarizing	enhancer	Exelixis	deficiencies	and	all	follow‐up	
crosses	for	each	Exelixis	line	is	found	in	Table	B.10.	
	
2.4.3	Deficiencies	lethal	in	combination	with	sda	
In	 addition	 to	 deficiencies	 that	 enhanced	 seizure	 susceptibility,	 we	 found	 two	
Exelixis	deficiencies	 that	 showed	partial	 synthetic	 lethality	 in	 combination	with	
sda	but	not	with	parabss1	and	eas	(Table	2.3).		To	determine	the	genes	underlying	
the	 lethality,	 we	 obtained	 overlapping	 deficiencies	 and	 several	 alleles	 of	
candidate	genes	to	cross	and	test	for	viability.		The	cross	between	Exel6263	and	
sda	produced	very	few	flies	with	the	genotype	Exel6263/sda.	Three	overlapping	
deficiencies	 were	 tested	 and	 we	 were	 able	 to	 narrow	 down	 the	 window	 of	
candidate	genes	to	a	region	of	approximately	6	Mbp	containing	12	genes	(Table	
2.4,	Figure	B.2.		Candidate	genes	can	be	found	in	Table	B.8).	
The	 second	 deficiency,	 Exel6214,	 crossed	 to	 sda,	 produced	 a	 low	 number	 of	
Exel6214/sda	progeny	compared	to	the	balancer	siblings	(14/80	total)	instead	of	
the	 expected	 50%	 of	 the	 total	 progeny.	 	 We	 tested	 three	 genes	 within	 this	
deficiency	 with	 sda	 to	 see	 if	 any	 of	 these	 might	 be	 the	 cause	 of	 the	 partial	
lethality.		While	the	genes	tested	did	not	cause	lethality	(Table	B.9),	one	of	these,	
similar	 (sima),	 caused	a	 large	enhancement	 in	bang‐sensitivity	when	crossed	to	
elav‐GAL4;	 sda	 (Figure	 2.4).	 	 However,	 tests	 of	 a	 deficiency	 overlapping	 sima	
(Df(3R)BSC502,	 #25006)	 did	 not	 confirm	 this	 enhancement	 in	
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Figure	 2.4	 	 Effects	 of	 neuron‐targeted	 RNAi	 knockdown	 in	 enhancing	 bang‐
sensitivity.		RNAi	targeted	to	all	neurons	by	crossing	elav‐GAL4;	sda	to	UAS‐RNAi	
constructs	 of	 putative	 sda	 enhancers.	 	 Data	 represented	 as	 fold	 change	 as	
compared	 to	 control	 (elav‐GAL4/+;	 sda/+).	 	 N≥69	 per	 RNAi	 line,	 except	 for	
CG18616	(N=13)	and	ccty	(N=17).	
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bang‐sensitivity,	though	the	larger	knockdown	provided	by	RNAi	targeted	only	to	
neurons	may	explain	the	difference	in	behavior	and	viability.			
 
2.5 Discussion 
2.5.1	Deficiency	screen	identifies	genes	that	are	able	to	enhance	seizures	
At	the	time	when	this	screen	was	designed	and	a	preliminary	set	of	deficiencies	
was	 tested,	 our	 current	knowledge	of	 the	 extant	Drosophila	 seizure	 excitability	
mutants	 showed	 a	 wide	 array	 of	 genes	 with	 disparate	 functions	 and	 no	 clear	
relationship	between	those	with	very	similar	behavioral	phenotypes,	such	as	the	
BS	mutants	which	all	displayed	a	stereotypical	seizure‐paralysis	behavior	after	a	
mechanical	 stimulus	 [22].	 	 For	 example,	 the	 gene	 product	 of	 sda	 is	 an	
aminopeptidase	[14],	the	gene	product	of	eas	is	an	ethanolamine	kinase	[23],	and	
the	product	of	another	BS	mutatione	technical	knockout	(tko)	is	a	mitochondrial	
ribosomal	protein	[24].	 	We	performed	this	deficiency	screen	using	one	of	these	
BS	lines,	sda,	in	order	to	find	interactors	that	may	help	us	to	elucidate	a	pathway	
that	might	underlie	the	seizure	phenotype,	and	perhaps	link	the	different	BS	lines	
together.	
	
Using	 sda	 as	 the	 sensitized	 seizure	 background,	 the	 Exelixis	 3R	 kit,	 and	
mechanically	 induced	seizures,	we	 found	19	Exelixis	deficiencies	 that	enhanced	
the	 BS	 phenotype	 of	 sda	 heterozygotes.	 	 With	 further	 testing	 using	 available	
deficiencies,	 transposon	 insertion	 lines,	 and	 UAS‐RNAi	 lines,	 we	 were	 able	 to	
identify	13	genes	as	candidate	enhancers	of	seizure	susceptibility.		The	products	
of	11	of	these	genes	have	known	functions	that	range	in	a	variety	of	processes.			
	
Only	one	of	the	enhancer	genes	found	in	this	screen,	CG9467,	encodes	a	protein	
directly	 associated	 with	 an	 ion	 channel.	 	 Though	 not	 much	 is	 known	 about	
CG9467,	the	gene	has	homology	to	the	human	epilepsy	gene	KCTD7	(potassium	
channel	 tetramerization	 domain‐containing),	 which	 functions	 in	 regulating	
potassium	 conductance	 in	 neurons	 [25].	 	 It	 is	 also	 involved	 as	 an	 auxiliary	
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Table	2.2	
Candidate	enhancers	of	sda	bang‐sensitivity	
	
Exelixis	
Deficiency	
Candidate	
Enhancer	
CG	No.	 Gene	name	 Function	 Biological	Processes	
Exel6151	 CG9755	 pumilio	(pum)	 translational	repressor	 synaptic	transmission	
dendrite	morphogenesis	
pole	cell	migration	
Exel6154		 CG9467	 		 oxidoreductase	activity	 oxidation‐reduction	
process	
potassium	ion	transport	
Exel6178		 CG14309	 		 unknown	 unknown	
Exel6196		 CG31140	 		 diacylglycerol	kinase	
activity	
lateral	inhibition	
Exel6214	 CG7951	 similar	(sima)	 signal	transducer	
activity	
positive	regulator	of	
transcription	
Exel6270		 CG42342	 		 unknown	 unknown	
Exel7305		 CG4591	 Tetraspanin	86D	
(Tsp86D)	
Cell	adhesion,	signal	
transduction	
nervous	system	
development	
Exel7317		 CG6359	 Sorting	nexin	3	
(Snx2)	
phosphatidylinositol	
binding	
Wnt	receptor	signaling	
pathway	
		 CG18616	 		 DNA‐binding	
transcription	factor	
DNA‐dependent	regulation	
of	transcription	
Exel7328		 CG4006	 Akt1	 protein	
serine/threonine	kinase	
many	developmental	
processes	
	 CG5952	 48	related	2	(fer2)	 DNA‐binding	
transcription	factor	
neuron	development	
locomotor	activity	
Exel7379		 CG1470	 Guanylyl	Cyclase	β	
(Gycβ)	
guanylate	cyclase	
activity	
cGMP	processing	
Exel9025		 CG1973	 yata	 protein	kinase	 protein	phosphorylation	
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subunit	of	GABAB	receptors	in	which	KCTDs	are	able	to	affect	the	kinetics	of	the	
GABAB		receptor	[26].	
	
The	 other	 nine	 genes	 found	 in	 this	 screen	 are	 not	 associated	 with	
channelopathies.		However,	since	our	candidate	gene	search	was	biased	towards	
those	that	have	significant	expression	in	the	nervous	system,	most	of	these	genes	
are	present	at	moderate	to	high	levels	in	brain	or	central	nervous	system,	so	it	is	
possible	 that	 many	 of	 these	 enhancer	 genes	 have	 a	 function	 in	 the	 nervous	
system.	 	 Some	 of	 the	 biological	 function	 categories	 that	 these	 genes	 fall	 under	
include	neural	development,	translational	control,	secretory	pathway,	and	others.	
	
2.5.2	Genes	affecting	neural	development	
Recently,	work	on	sda	has	shown	that	the	seizure	phenotype	is	due	to	increased	
persistent	Na+	current	in	the	central	neurons	as	well	as	changes	to	Ca2+	and	Na+	
conductances	 in	motoneurons	of	sda	 larvae.	 	The	role	of	 the	aminopeptidase	 in	
causing	 this	 increase	of	Na+	 current	 is	 still	 unknown,	 though	 it	 is	hypothesized	
that	the	change	in	Na+	currents	and	ion	conductances	alters	neural	development	
[15].	 	 It	 is	 possible	 that	 in	 the	 presence	 of	 other	 mutations	 that	 affect	 neural	
development,	the	effects	of	sda	activity	on	nervous	system	development	might	be	
exacerbated.			
	
One	 of	 the	 genes	 found	 in	 this	 screen,	 CG31140,	 is	 a	 diacylglycerol	 kinase	 that	
may	be	involved	in	neural	glial	development	through	lateral	inhibition.		This	gene	
is	 downregulated	 in	 the	 glial	 cells	missing	 mutant,	 where	 glia	 are	 transformed	
into	 neurons	 [27].	 	 Interestingly,	 this	 is	 the	 only	 gene	 from	 our	 screen	 that	
appears	 to	 enhance	 BS	 seizure	 in	 the	 sda	 heterozygote	 but	 not	 the	 parabss1	
heterozygote.		Tetraspanin	86D	(Tsp86D)	is	another	enhancer	found	in	the	screen.		
This	gene	encodes	a	 transmembrane	protein	expressed	throughout	 the	nervous	
system	and	 is	 known	 to	be	 required	 for	normal	 formation	of	 the	ventral	 nerve	
cord	and	proper	axon	guidance	[28],	[29].		Another	gene,	48	related	2	(fer2),	is	a		
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Table	2.3	
3R	Exelixis	deficiencies	that	show	partial	synthetic	lethality	in	combination	with	
slamdance	
	
slamdance	 parabangsenseless	 easily	shocked	
Exel6263/TM6B,	Tb	 Exel6263	 female	 0	 46	 35	
(#7730)	 		 male	 5	 49	 18	
		 TM6B,	Tb	 female	 43	 33	 23	
		 		 male	 37	 20	 21	
Exel6214/TM6B,	Tb	 Exel6124	 female	 11	 52	 53	
(#7692)	 		 male	 3	 42	 32	
		 TM6B,	Tb	 female	 38	 39	 50	
		 		 male	 29	 36	 21	
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transcription	 factor	 required	 for	 the	 development	 of	 ventral	 lateral	 neurons,	
which	are	known	as	pacemaker	neurons	for	circadian	locomotor	rhythms	[30].			
	
2.5.3	Genes	affecting	the	secretory	pathway	
Neurons	 are	 highly	 reliant	 on	 the	 secretory	 pathway	 for	 normal	 function.		
Packaging,	 transporting,	 and	 releasing	 neurotransmitters	 and	 peptides	 are	 all	
carefully	regulated	and	involve	many	components.		One	of	the	BS	enhancer	genes,	
yata,	 is	believed	 to	be	 involved	 in	 the	 sorting	of	vesicles	 in	 regulated	 secretory	
pathways,	such	as	those	needed	for	synaptic	transmission	[31].		Another	study	of	
yata	 suggests	 that	 it	 is	needed	 for	regulation	of	protein	 localization,	specifically	
the	 amyloid	 precursor‐like	 (APPL)	 protein	 in	 Drosophila	 [32].	 	 Another	 BS	
enhancer	 and	 secretory	 pathway	 gene,	 Sorting	 nexin	 3	 (Snx3),	 is	 a	 protein	
expressed	in	cytoplasm	and	is	a	part	of	the	retrograde	transport	from	endosomes	
to	 the	 trans‐golgi	network	 [33].	 	Though	 they	both	are	able	 to	 increase	 seizure	
susceptibility	in	BS	heterozygotes,	the	method	by	which	these	genes	cause	this	is	
unknown.	
	
2.5.4	Genes	affecting	O2	and	NO	detectors	
Sima	 is	 the	Drosophila	version	of	mammalian	hypoxia	 inducible	 factor	α	 (HIF‐α)	
and	is	regulated	by	oxygen	levels	by	a	protein	domain	that	functions	as	an	oxygen	
sensor	[34].		The	normal	function	of	Sima	is	to	detect	hypoxia,	which	leads	to	the	
cell’s	 response	 to	 low	 oxygen	 conditions	 [35].	 	 In	 the	 case	 of	 the	 BS	 enhancer	
screen,	it	is	possible	that	the	knockdown	of	Sima	due	to	RNAi	renders	cells	unable	
to	respond	to	low	oxygen	levels	during	or	after	a	seizure,	leading	to	an	increase	in	
severity.	
	
Similarly,	the	BS	enhancer	gene	guanylyl	cyclase	β	(	gycβ)	is	a	subunit	of	a	nitric	
oxide	(NO)	sensor	in	the	brain	[36].		NO	is	able	to	function	as	a	signaling	molecule	
and	 as	 a	 neurotransmitter,	 and	 is	 reported	 to	 have	 a	 connection	 with	 human	
epilepsy,	 though	 various	 studies	 have	 given	 mixed	 results	 (reviewed	 in	 [37]).			
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Table	2.4	
Follow‐up	deficiency	testing	for	lethality	caused	by	Exel6263	
	
Deficiency	
Stock	
Number	 Breakpoints	 Viability	when	crossed	to	sda
Df(3R)Exel6263	 7730	 84E6‐‐84E13	 Lethal	
Df(3R)BSC196	 9200	 84E6‐‐84E11	 Lethal	
Df(3R)BSC196	 9622	 84E6‐‐84E8	 Lethal	
Df(3R)BSC222	 9699	 84E8‐‐84F6	 Viable	
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gycβ	 along	with	 α	 subunits	 regulates	 2nd	messenger	 pathways	 that	 result	 from	
the	presence	of	NO	due	to	neural	activity	or	stressors	[38].		Work	has	shown	that	
gycβ	 may	 be	 able	 to	 use	 the	 presence	 of	 NO	 due	 to	 neural	 activity	 to	 detect	
coincidence	of	signals	received	by	a	neuron	[39].			
	
2.5.5	Translational	control	and	neuronal	excitability	
Translational	 control	 is	 essential	 for	 gene	 regulation	 during	 all	 stages	 of	
development,	 often	 through	 mechanisms	 such	 as	 polyadenylation	 and	
deadenylation,	 recruiting	 4E	 binding	 proteins,	 repression	 by	 microRNAs,	 and	
ribosomal	 binding	 regulation	 (reviewed	 in	 [40]).	 	 Studies	 in	 Drosophila,	 C.	
elegans,	 and	 Xenopus	 have	 shown	 that	 translational	 control	 is	 required	 for	
oogenesis	 and	 early	 development	 [41],	 [42].	 	 However,	 evidence	 suggests	 that	
translational	 control	 is	 connected	 to	 neuronal	 excitability	 as	 well,	 such	 as	 in	
regulating	neural	development	(reviewed	in	[43]).		Therefore,	it	is	not	surprising	
that	several	of	the	genes,	specifically	Akt,	pumilio	(pum),	and	CG18616,	found	in	
this	 screen	 are	 involved	 in	 translational	 control.	 	 Akt	 is	 a	 part	 of	 a	 pathway	
responsible	for	elF2α	phosphorylation	in	response	to	stress.		The	end	product	of	
this	 pathway	 is	 the	 inhibition	 of	 mRNA	 translation	 [44].	 	 CG18616	 is	 a	
transcription	 factor	 that	 is	 the	 fly	homolog	of	human	NOT10,	which	 is	a	part	of	
the	 carbon	 catabolite‐repression	 4‐NOT	 (CCR4‐NOT)	 complex	 involved	 in	
deadenylation	of	mRNA	[45].	 	Though	not	much	is	known	about	CG18616	itself,	
the	CCR4‐NOT	complex	is	suggested	to	be	a	“chaperone	platform”	present	in	most	
parts	of	 the	organism	 that	helps	 to	 regulate	and	 link	multiple	proteins	 that	are	
involved	in	different	mechanisms	of	translational	control	[46].	
	
Of	the	genes	found	in	the	screen,	pum	was	the	only	gene	previously	reported	to	
increase	neuronal	excitability.	 	Pum	 is	a	 translational	 repressor	best	known	 for	
its	 function	 in	 early	 development	 where	 it	 is	 implicated	 in	 maintenance	 of	
germline	 stem	 cells	 and	 establishing	 the	 anterior‐posterior	 axis	 through	
regulating	expression	of	hunchback	[47],	[48].		More	recent	work	has	shown	that	
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pum	 regulates	 neuronal	 excitability.	 	 Specifically,	 Pum	 is	 involved	 in	 the	
formation	of	higher	order	dendrites	[49].		This	function	in	dendritogenesis	is	also	
supported	 by	 evidence	 from	 the	 mammalian	 homolog	 of	 pum,	 Pumilio2	 [50].		
Another	 study	 showed	 that	 levels	 of	 pum	 mRNA	 is	 regulated	 by	 amounts	 of	
neuronal	 activity,	 and	 that	 lowering	 levels	 of	 Pum	 itself	 increased	 the	 mRNA	
levels	 of	 a	 voltage‐gated	Na+	 channel	 [51].	 	 Therefore,	 it	was	 not	 surprising	 to	
identify	pum	 as	 an	 enhancer	 of	 seizure	 behavior.	 	 It	 is	 interesting	 to	 note	 that	
many	 genes	 that	 are	 associated	 with	 pum,	 either	 by	 functioning	 in	 the	 same	
translational	regulatory	pathway,	or	by	being	regulated	by	Pum,	have	also	been	
connected	to	neuronal	excitability	[49],	[52],	[53]	and	suggests	that	further	study	
of	pum	and	associated	genes	using	this	screening	method	may	result	in	discovery	
of	more	enhancers	of	BS	seizures.	
	
2.5.6	Deficiency	screening	for	enhancers	of	bang‐sensitivity	
Our	genetic	screen	represents	one	of	the	few	to	search	for	enhancers	of	seizure	
susceptibility	using	a	BS	mutant	as	 the	sensitized	background.	 	We	expected	 to	
find	 both	 general	 enhancers	 of	 seizure	 as	 well	 as	 possible	 interactors	 of	 the	
neural	membrane	aminopeptidase	encoded	by	sda	[14].		Through	this	screen,	we	
identified	12	known	genes,	excluding	pum,	that	were	previously	not	connected	to	
any	 phenotype	 related	 to	 enhancing	 neuronal	 excitability	 or	 seizures.	 	 The	
deficiency	 screening	 method	 allowed	 for	 relatively	 quick	 forward	 genetic	
screening	 of	 specific	 regions	 of	 the	 genome	 followed	 up	 by	 a	 reverse	 genetics	
approach	of	determining	if	mutations	of	specific	genes	can	increase	BS	behavior.		
Enhancer	screens	typically	 identify	components	of	pathways	[54]	but	the	genes	
we	 identified	may	 not	 be	 specific	 enhancers	 of	 sda	 as	 they	 enhanced	multiple	
bang‐sensitive	 lines,	 though	 further	 testing	 is	 needed	 to	 confirm	 this.	 	 One	
interesting	result	is	the	finding	of	two	deficiencies	that	appear	to	be	semi‐lethal	
in	 combination	 with	 sda.	 	 Though	 the	 identity	 of	 the	 genes	 that	 cause	 this	
synthetically	 lethal	 phenotype	 is	 unknown,	 they	 may	 have	 a	 more	 direct	
connection	to	sda	function.	
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Although	 this	 screen	 only	 covered	 65%	 of	 chromosome	 3R,	 we	 believe	 this	
method	can	be	effectively	extended	to	encompass	most	of	the	Drosophila	genome	
since	 the	 combination	 of	 Bloomington	 Deficiency	 Project,	 Exelixis,	 and	 the	
DrosDel	 deficiency	 collections	 together	 cover	 between	 94‐98.9%	 of	 genes	 on	
each	 chromosome.	 	 The	 initial	 stage	 of	 the	 screen	 is	 quick	 and	 efficient	 due	 to	
needing	only	 one	 generation	of	 crosses,	 the	 follow‐up	 stages	 can	be	more	 time	
consuming	 since	 a	 large	 collections	 of	 stocks	 need	 to	 be	 obtained	 for	 the	
subsequent	 testing.	 	 This	was	 one	 of	 the	 reasons	 that	 our	 search	 for	 enhancer	
genes	was	 biased	 towards	 those	with	 neuronal	 expression,	 in	 order	 to	 narrow	
down	our	search	pool	of	genes	as	much	as	possible.			
	
One	note	 to	make	about	 this	 screening	method	 is	 that	many	of	 the	deficiencies	
that	 were	 found	 to	 enhance	 BS	 phenotype	 penetrance	 gave	 a	 much	 higher	
percentage	of	 flies	 seizing	 than	did	 any	of	 the	 individual	 enhancer	 genes.	 	 This	
can	 be	 due	 to	 the	 deficiency	 causing	 an	 entire	 deletion	 of	 the	 gene,	 while	 the	
alleles	could	be	hypomorphs,	but	this	can	also	be	due	to	multiple	genes	within	the	
deficiency	 that	 contributing	 to	 the	 BS	 phenotype.	 	 For	 example,	 alleles	 of	 pum	
never	enhanced	the	BS	phenotype	as	much	as	the	Exelixis	deficiency	containing	
pum.	 	 However,	 the	 deficiency	 also	 contained	 two	 other	 genes	 that	 slightly	
enhanced	 the	 seizure	 penetrance,	 and	 it	 may	 be	 possible	 that	 these	 genes	 in	
combination	 with	 pum	 allowed	 the	 Exelixis	 deficiency	 to	 give	 a	 stronger	
phenotype.	 	 In	 future	 iterations	of	 this	 screen,	 it	may	be	 important	 to	 consider	
other	genes	that	enhance	the	BS	phenotype	instead	of	selecting	only	the	strongest	
one.	
	
In	 summary,	 in	 this	 work	 we	 screened	 for	 genes,	 which	 when	 mutated	 or	
knocked	down,	enhance	the	penetrance	of	the	BS	seizure	phenotype.		The	genes	
found	 in	 this	 work	 encode	 a	 range	 of	 different	 products	 such	 as	 kinases,	
transcription	 factors,	 and	 translational	 repressors,	 among	others.	 	 Though	 they	
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mostly	have	unrelated	 functions,	 their	effects	on	enhancing	bang‐sensitivity	are	
almost	 identical,	 varying	 only	 in	 the	 actual	 magnitude	 of	 seizure	 penetrance.		
Most	 of	 these	 genes	 enhanced	 at	 least	 two	 BS	 lines,	 indicating	 that	 they	 may	
contribute	 to	a	general	 increase	 in	bang	sensitivity,	 though	one	gene,	CG31440,	
has	 a	 specific	 effect	 on	 sda.	 	 Since	 our	 screen	 generally	 focused	 on	 genes	 that	
were	 expressed	 at	 moderate	 to	 high	 levels	 (according	 to	 FlyAtlas	 Anatomical	
Expression	 Data)	 in	 the	 nervous	 system,	 a	 large	 number	 of	 the	 genes	 we	
identified	 as	 enhancers	 have	 known	 roles	 in	 the	 nervous	 system,	 though	 none	
have	 been	 directly	 implicated	 in	 seizure	 behavior	 or	 increases	 in	 neuronal	
excitability.		Further	work	on	these	genes	alongside	the	BS	mutants	may	help	us	
to	 understand	 how	mutations	 in	 these	 genes	 can	 lead	 to	 increases	 in	 neuronal	
excitability.	
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CHAPTER	3	
THE	TRANSLATIONAL	REPRESSOR	PUMILIO	IS	NECESSARY	DURING	NERVOUS	
SYSTEM	DEVELOPMENT	FOR	NORMAL	NEURONAL	EXCITABILITY	IN	ADULT	
DROSOPHILA	
 
3.1  Abstract 
The gene pumilio (pum) encodes a translational repressor well known in Drosophila 
development to regulate anterior-posterior patterning and germ line maintenance.  
More recent work has implicated this gene in later stages of development, specifically 
in the nervous system, to regulate processes such as expression of ion channels and 
dendrite arborization.  Studies in other organisms also support the function of pum in 
neuronal development and excitability.  We discovered that pum is also able to 
enhance seizure susceptibility in a sensitized background when mutated, and therefore 
we have used this phenotype to learn more about the timing and location of Pum 
function with relation to neural development.  Using behavioral tests, 
electrophysiology, and immunohistochemistry, we show that the effect of pum 
mutation on neuronal excitability is greatest when there is a reduction of Pum levels in 
cholinergic and GABAergic neurons, in comparison to other types of neurons, and that 
this reduction is required at multiple stages of development. 
 
3.2  Introduction 
Translational	 control	 is	 an	 essential	 component	 of	 development	 in	 many	
organisms	and	affects	the	regulation	of	a	wide	range	of	mRNAs	through	various	
mechanisms	(reviewed	in	[1]).		Much	work	has	been	done	in	showing	the	role	of	
translational	control	in	maintenance	of	germ	cells	and	in	the	cell	cycle,	especially	
in	 Drosophila	 and	 C.	 elegans	 [2].	 	 	 However,	 increasing	 evidence	 reveals	 the	
importance	of	translational	control	in	the	normal	development	and	functioning	of	
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the	 nervous	 system	 [3],	 [4]	 by	 providing	 a	 means	 of	 post‐transcriptionally	
regulating	 gene	 expression	 to	 specific	 locations	 where	 the	 translation	 of	 the	
mRNA	 is	needed.	 	 Since	neurons	are	specialized	cells	and	highly	polarized,	 it	 is	
essential	 that	gene	expression	 is	 regulated	at	 specific	 sites	of	 the	cell	 to	ensure	
proper	development.		Also,	since	neurons	are	compartmentalized	and	often	have	
axons	and	dendrites	that	may	extend	away	from	the	cell	body,	regulating	mRNAs	
already	 present	 in	 these	 structures	 provides	 a	 fast	method	 of	 controlling	 gene	
expression,	instead	of	using	de	novo	mRNA	synthesis	[5],	[6].	
	
One	 example	 of	 translational	 control	 by	 a	 gene	 that	 is	 essential	 both	 in	 early	
embryogenesis	and	in	neural	development	is	that	of	the	gene	pumilio	(pum).	 	In	
Drosophila,	Pum	protein	functions	as	a	translation	repressor	as	a	part	of	the	PUF	
RNA‐binding	protein	family	and	has	orthologs	in	worms	[7],	plants	[8],	Xenopus	
[9],	mice	[10],	and	humans	[11].		Pum	is	known	to	have	a	role	in	regulating	many	
functions,	and	has	been	well	characterized	 in	early	stages	of	 the	Drosophila	 life	
cycle,	 including	 establishment	 of	 the	 anterior‐posterior	 axis,	 abdominal	
segmentation	 [12],	 and	maintenance	 of	 germline	 stem	 cells	 [13].	 	 Early	 on,	 the	
main	 focus	 of	 pum	 research	 was	 on	 its	 role	 regulating	 embryonic	 anterior‐
posterior	axis	 formation	 through	several	genes	such	as	hunchback.	 	However,	a	
new	mutant,	 named	 bemused,	 was	 found	 as	 a	 behavioral	mutant	with	 reduced	
coordination	and	flight	ability	[14]	and	was	eventually	discovered	to	be	an	allele	
of	 pum	 [15].	 	 From	 this	 point,	 a	 number	 of	 discoveries	 were	 made	 on	 the	
involvement	of	pum	in	neuronal	excitability.	
	
As	Pum	was	revealed	to	be	involved	in	several	adult	processes,	many	efforts	were	
made	 to	 discover	 its	 targets	 and	 gain	 a	 more	 thorough	 understanding	 of	 its	
functions	 [16],	 [17].	 	 Pum	 is	 believed	 to	 have	 a	 wide	 range	 of	 targets	 for	
repression,	 as	 the	 consensus	mRNA	binding	 sequence	 for	Pum	 is	 found	 in	over	
1000	genes	[16].		Furthermore,	the	mRNAs	known	to	be	localized	to	the	synapse	
were	screened	for	pum	mRNA	binding	by	using	computational,	biochemical,	and	
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in	 vivo	 assays	 [17].	 	 A	 screen	 searching	 for	 genes	 involved	 in	 learning	 and	
memory,	by	both	mutagenesis	and	microarray,	revealed	the	gene	pum	as	well	as	
staufen,	a	gene	which	has	a	Pum	binding	sequence	in	its	mRNA,	suggesting	Pum’s	
role	 in	 synaptic	modification	 [18].	 	 More	 evidence	 for	 this	 came	 from	 another	
study	 showing	 that	 the	 translational	 control	by	Pum	does	 indeed	play	a	 role	 in	
synaptic	 modification,	 specifically	 in	 the	 elaboration	 of	 higher	 order	 dendrites	
[19].	 	This	was	 followed	up	by	work	on	pum	 in	 the	mouse	model	 showing	 that	
microRNAs	regulate	levels	of	Pum	in	order	to	control	dendritogenesis	[20].			
	
More	 direct	 evidence	 that	pum	 is	 involved	 in	 synaptic	 transmission	 came	 from	
another	study	when	the	pum	allele,	pumbemused,	crossed	into	a	seizure‐susceptible	
background	 showed	 that	 levels	 of	 pum	mRNA	 itself	 are	 regulated	 by	 neuronal	
activity.	 	 Reduction	 in	 Pum	 resulted	 in	 an	 increase	 of	 paralytic	 (para)	 mRNA,	
which	 encodes	 a	 voltage‐gated	 Na+	 channel.	 Likewise,	 overexpression	 of	 Pum	
caused	 reduction	 in	 the	 magnitude	 of	 the	 Na+	 current	 in	 motoneurons	 [21].		
However,	 while	 there	 is	 evidence	 connecting	 pum	 to	 functions	 in	 synaptic	
transmission	 and	 neuronal	 excitability,	 its	 expression	 pattern	 in	 the	 adult	
nervous	 system,	 the	 effects	 of	 pum	 mutations	 on	 the	 behavior	 of	 seizure‐
susceptible	 mutants,	 and	 the	 importance	 of	 Pum	 in	 specific	 stages	 of	
development	for	normal	neuronal	excitability	remains	unknown.	
	
To	 better	 understand	 the	 role	 of	 pum	 in	 regulating	 neuronal	 excitability,	 we	
investigated	 its	effect	on	seizure	behavior	as	well	as	 its	expression	in	the	 larval	
and	adult	nervous	system.	 	Behavioral	analysis	revealed	that	a	decrease	in	Pum	
due	to	mutation	increases	the	penetrance	of	seizure	in	a	sensitized	bang‐sensitive	
(BS)	background.		This	increase	in	BS	seizure	was	apparent	even	when	the	Pum	
allele	 is	 heterozygous.	 	We	 show	 that	 this	 seizure	 behavior	 increase	 correlates	
with	 a	 lowering	 of	 the	 voltage	 of	 the	 stimulus	 required	 to	 directly	 induce	 a	
seizure.	 	 In	 analyzing	 the	 expression	 pattern	 of	 Pum,	 we	 found	 that	 all	 cells	
positive	for	Pum	also	are	positive	for	neural	markers,	indicating	that	the	protein	
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is	 present	 only	 in	 neurons.	 	 Panneural	 knockdown	of	 Pum	using	RNAi	 reduces	
most	of	 its	expression	 in	 the	brain.	 	Targeted	knockdown	of	Pum	specifically	 in	
cholinergic	 and	 GABAergic	 neurons	 produces	 a	 strong	 increase	 in	 seizure	
behavior	as	well.		Finally	we	show	that	reduction	of	Pum	in	both	larval	and	adult	
stages	is	needed	in	order	for	the	increase	in	BS	seizure	behavior	to	be	apparent.		
Our	 results	 show	 that	 the	 function	of	Pum	 in	neurons	during	development	and	
adult	stages	is	necessary	for	normal	neuronal	excitability	at	the	adult	stage.		
	
3.3 Methods 
Fly	stocks	
Flies	 were	 maintained	 on	 standard	 yeast	 and	 glucose	 media	 at	 25°C.	 	 Bang‐
sensitive	 stocks	 slamdance,	 easily	 shocked,	 and	 parabangsenseless	 were	 a	 gift	 from	
Ronald	 Hoy.	 	 Except	 when	 mentioned,	 all	 other	 stocks	 are	 available	 from	 the	
Drosophila	 Stock	 Center	 (accompanied	 by	 stock	 number).	 	 w1118	 (#5905	 and	
#6326)	 crossed	 to	 bang‐sensitive	 stocks	 were	 used	 as	 a	 behavioral	 control.		
Deficiencies	 used	 that	 affect	 pumilio	 include,	Df(3R)by10,	 red1	 e1/TM3,	 Sb1	 Ser1	
(#1931),	 w1118;	 Df(3R)Exel6151,	 P{w+mC=XP‐U}Exel6151/TM6B,	 Tb1	 (#7630),	
w1118;	 Df(3R)Exel6152,	 P{w+mC=XP‐U}Exel6152/TM6B,	 Tb1	 (#7631),	 and	 w1118;	
Df(3R)BSC666/TM6C,	 Sb1	 cu1	 (#26518).	 	 pumilio	 alleles	 used	 include	 w*;	
P{w+mC=lacW}pumbem/TM6	(#6782),	P{ry+t7.2=PZ}pum01688	ry506/TM3,	ryRK	Sb1	Ser1	
(#11544),	and	y1	w67c23;	P{y+t7.7	w+mC=wHy}pumDG05207/TM3,	Sb1	Ser1	(#21042).	
	
In	 tests	 using	 knockdown	 of	 pumilio,	we	 crossed	 a	 pum‐RNAi	 line	 (pum‐RNAi,	
#101399,	 Vienna	 Drosophila	 RNAi	 Center)	 to	 various	 GAL4	 lines.	 	 For	 tests	
requiring	overexpression	of	pumilio,	we	crossed	UAS‐pum	(gift	of	Michael	Stern)	
to	 various	 GAL4	 lines.	 	 For	 specific	 temporal	 control	 of	 pumilio	 RNAi,	 we	
recombined	 pum‐RNAi	 with	 a	 Gal80ts	 line,	 w*;	 P{w+mC=tubP‐GAL80ts}10;	
TM2/TM6B,	 Tb1	 (#7108)	 to	 be	 used	 with	 GAL4	 lines.	 	 Likewise,	 for	 temporal	
control	of	UAS‐pum,	we	recombined	UAS‐pum	with	the	same	Gal80ts	line.	
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Figure	3.1		Exel6151	enhances	bang‐sensitivity	penetrance.		Exel6151	deficiency	
was	 crossed	 to	 three	 bang‐sensitive	 lines	 and	 tested	 for	 seizure	 penetrance.		
N≥60	for	each	genotype.			
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GAL4	 lines	 used	 include	 promoters	 of	 the	 following	 genes:	 Choline	
acetyltransferase	 (cha)	 (w1118;	 P{w+mC=Cha‐GAL4.7.4}19B/CyO,	
P{ry+t7.2=sevRas1.V12}FK1)	 (#6798)	 and	 Vesicular	 acetylcholine	 transporter	
(VAChT)	 (w1118;	 P{GMR55G09‐GAL4}attP2)	 (#46075)	 to	 target	 cholinergic	
neurons,	vesicular	glutamate	 transporter	 (P{w+mC=VGlut‐GAL4.D}1,	w*)	 (#24635)	
to	target	glutamatergic	neurons,	reversed	polarity	(w1118;	P{w+m*=GAL4}repo/TM3,	
Sb1)	 (#7415)	 to	 target	 glia,	 β	 amyloid	 protein	 precursor‐like	 (P{w+m*=Appl‐
GAL4.G1a}1,	 y1	 w*)	 (#32040)	 to	 target	 neurons,	 tyrosine	 decarboxylase	 (w*;	
P{w+mC=Tdc2‐GAL4.C}2)	(#9313)	to	target	octopaminergic	neurons,	Actin	 (y1	w*;	
P{Act5C‐GAL4‐w}E1/CyO)	 (#25374)	 to	 target	 all	 cells,	 slit	 (w*;	 P{w+mC=GAL4‐
sli.S}3)	 (#9580)	 to	 target	midline	 glia,	elav	 (P{w+mW.hs=GawB}elavC155)	 (#458)	 to	
target	 neurons,	 and	 Gad2B‐GAL4	 (gift	 of	 Leslie	 Griffith)	 to	 target	 GABAergic	
neurons.	
	
Larval	Immunohistochemistry	
Wandering	 third	 instar	 larvae	 were	 dissected	 in	 cold	 HL3.1	 without	 Ca2+	 and	
fixed	in	4%	paraformaldehyde	for	30	minutes.		Larvae	fillets	were	washed	three	
times	quickly	and	three	times	15	minutes	in	PBS	+	0.3%	Triton‐X	+	10	mM	Tris	
HCl	pH	7.5	(PBST)	and	then	blocked	in	10%	donkey	serum	for	one	hour	at	room	
temperature.	 	The	 larvae	were	 incubated	 in	primary	antibody	overnight	at	4°C,	
then	washed	again	in	PBST	three	times	quickly	and	three	times	15	minutes.		After	
this,	 the	 larvae	were	 put	 in	 secondary	 antibody	 in	 PBST	 +	 10%	donkey	 serum	
incubation	for	four	hours	at	room	temperature,	and	then	washed	again	in	PBST	
wash	 solution,	 at	 which	 point	 they	 were	 mounted	 on	 a	 glass	 slide	 using	
Vectashield	(Vector	Labs)	which	are	then	stored	in	the	dark	at	4°C.	
	
Primary	antibodies	were	used	as	follows:	 	Anti‐pumilio	A	(rat,	1:1000,	gift	 from	
Paul	 MacDonald),	 anti‐elav	 (mouse,	 1:100,	 Developmental	 Studies	 Hybridoma	
Bank),	anti‐βgal	(mouse,	1:200,	Promega),	anti‐GFP	(rabbit,	1:2000,	 Invitrogen).		
Secondary	 antibodies	 are	 as	 follows:	 	 goat	 anti‐rat	 488	 (Invitrogen),	 goat	 anti‐	
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Figure	 3.2	 	 Seizure	 threshold	 in	 bang‐sensitive	 heterozygotes	 reduced	 by	
Exel6151	 .	 	Bang‐sensitive	 sda	 and	parabss1	 flies	were	 crossed	 to	either	w1118	 or	
Exel6151	and	the	progeny	tested	for	seizure	penetrance.	 	p<0.05.	 	N≥5	for	each	
genotype.	
* 
* 
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rabbit	 488	 (Invitrogen),	 donkey	 anti‐mouse	 Cy3	 highly	 adsorbed	 (Jackson	
Immunoresearch).		All	concentrations	for	secondary	antibodies	were	1:1000.	
	
Adult	Immunohistochemistry	
Adult	brains	were	prepared	as	follows:	Anaesthetized	adults	were	briefly	dipped	
into	ethanol	and	pinned	in	sylgard	dishes.		The	cuticle	surrounding	the	head	and	
thorax	was	removed	and	the	brain	and	ventral	nerve	cord	were	moved	to	a	4%	
paraformaldehyde	 solution	 for	 20	minutes.	 	 The	brains	were	 briefly	washed	 in	
PBS	 and	 then	 quickly	 rinsed	 three	 times	 and	 15	minutes	 three	 times	 in	 PBST.		
Brains	were	then	blocked	in	PBST	+	10%	donkey	serum	for	one	hour	and	placed	
in	 primary	 antibody	 overnight	 at	 4°C.	 	 The	 brains	were	 given	 three	 quick	 and	
three	15	minute	washes	in	PBST	and	placed	in	secondary	antibody	overnight	at	
4°C.		The	brains	were	washed	overnight	in	wash	solution,	after	which	they	were	
mounted	 on	 glass	 slides	 in	 Vectashield	 (Vector	 Labs)	 with	 hole	 punch	
reinforcement	sticker	used	as	a	spacer	between	the	slide	and	cover	slip,	and	then	
stored	in	the	dark	at	4°C.	
		
The	primary	 antibodies	 used	 are	 as	 follows:	 anti‐pumilio	B	 (rat,	 1:1000,	 gift	 of	
Paul	 Macdonald),	 anti	 elav	 (mouse,	 1:200,	 Developmental	 Studies	 Hybridoma	
Bank),	anti‐bruchpilot	 (mouse,	1:100,	Developmental	Studies	Hybridoma	Bank),	
anti‐GFP	 (rabbit,	 1:2000,	 Invitrogen),	 and	 anti‐βgal	 (mouse,	 1:200,	 Promega).		
Secondary	 antibodies	 are	 as	 follows:	 	 goat	 anti‐rat	 488	 (Invitrogen),	 goat	 anti‐
rabbit	 488	 (Invitrogen),	 donkey	 anti‐mouse	 Cy3	 (#715‐165‐151,	 Jackson	
Immunoresearch),	 goat	 anti‐mouse	 Alexa	 594	 (Invitrogen).	 	 All	 concentrations	
for	secondary	antibodies	were	1:1000.			
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	Figure	3.3		Alleles	of	the	gene	pumilio	enhance	the	penetrance	of	bang‐sensitivity	
of	 (A)	 parabss1	 and	 (B)	 slamdance	 heterozygotes	 compared	 to	 parabss1/+	 and	
sda/+,	respectively	heterozygotes	and	tested	by	vortexing.	N≥40	for	each	allele.	
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Electrophysiology	
Electrophysiology	was	based	on	Drosophila	 seizure	assays	 for	epilepsy	mutants	
[22].	 	 Adult	 flies	 2‐5	days	 post	 eclosion	were	 sorted	 into	 vials	 the	day	prior	 to	
recording	and	allowed	 to	recover.	 	Flies	were	 individually	handled	without	CO2	
anesthesia	using	a	modified	Tetra	Whisper	100	aquarium	pump	and	mounted	on	
dental	wax	on	 a	 glass	 slide,	 leaving	 the	dorsal	 surface	of	 the	 fly	 exposed.	 	 Two	
electrodes	 were	 inserted	 into	 the	 head	 underneath	 the	 antennae,	 a	 recording	
electrode	 inserted	 into	 the	 thorax,	 and	 the	neutral	 electrode	 into	 the	abdomen.		
The	 stimulating	 electrode	 was	 connected	 to	 the	 Grass	 S48	 Stimulator	 (Grass	
Instruments),	and	the	recording	electrodes	to	the	differential	AC	amplifier	(Model	
1700,	 A‐M	 Systems)	 to	 the	 oscilloscope	 (TDS1002B,	 Tektronix).	 	 All	 electrodes	
were	made	of	 tungsten	 and	 the	 ends	 stripped	of	 insulation.	 	 To	 induce	 seizure	
behavior,	stimuli	of	varying	voltage	were	given	to	the	flies	(300	ms	train	at	200	
pps,	each	pulse	being	0.5	ms).		Recordings	were	acquired	through	Digidata	1322A	
(Axon	Instruments)	and	recorded	using	Clampex	8.2	(Axon	Instruments).	
	
Imaging	
All	 confocal	 imaging	 was	 done	 using	 on	 the	 Leica	 SP2	 at	 the	 Cornell	 Imaging	
Facility.	 	 Images	were	taken	using	either	the	40x	oil	 immersion	lens	and	20x	or	
63x	 water	 immersion	 lens	 at	 1x	 or	 2x	 zoom.	 	 All	 images	 were	 cropped	 using	
Adobe	 Photoshop	 CS4	 or	 Adobe	 Photoshop	 Elements	 10	 and	 figures	 were	
arranged	using	Adobe	Illustrator	CS4.	
	
Statistics	
All	 electrophysiology	 data	 is	 shown	 using	mean	 ±	 standard	 error	 of	 the	mean	
(SEM).		Significance	is	considered	at	p<0.05	and	is	determined	using	the	unpaired	
t‐test.	
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Figure	3.4	 	Seizure	threshold	of	parabss1	heterozygotes	are	reduced	by	alleles	of	
pum.	 	 parabss1	 flies	 were	 crossed	 to	 various	 pum	 alleles	 and	 tested	 for	 seizure	
after	vortexing.	 	The	threshold	parabss1/+;	pum01688/+	 is	significantly	 lower	than	
that	 of	 parabss1/+,	 p<0.01.	 	 parabss1/+;	 pumbem/+	 seizure	 threshold	 is	 also	
significantly	lower	than	control,	p<0.05.		N>9	for	each	category	except	pumDG0527,	
where	N=3.	
* 
*
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3.4 Results	
3.4.1	Mutations	in	pumilio	enhance	penetrance	and	threshold	of	seizure	behavior	in	
a	bang‐sensitive	background	
In	 a	 previous	 mutant	 screen,	 we	 searched	 for	 deficiencies	 that	 increased	 the	
occurrence	 of	 seizures	 in	 a	 sensitized	 seizure‐susceptible	 background.	 	 This	
screen	was	performed	in	the	slamdance	(sda)	background,	which	is	a	member	of	
the	 group	 of	Drosophila	 seizure	mutants	 known	 as	 bang‐sensitives,	 due	 to	 the	
phenotype	 of	 displaying	 strong	 seizures	 after	 being	 given	 a	 mechanical	 or	
electrical	stimulus.		One	of	the	deficiencies	found	in	this	screen	with	the	strongest	
effects	 on	 increasing	 seizure	 penetrance	 in	 sda	 heterozygotes	 was	 the	 Exelixis	
deficiency	 Exel6151.	 	 Further	 behavior	 testing	 showed	 that	 this	 deficiency	
enhanced	 bang‐sensitivity	 in	 two	 other	 bang	 sensitive	 lines,	paralyticbangsenseless1	
(parabss1)	and	easily	shocked	(eas)	(Figure	3.1).		To	confirm	that	this	enhancement	
in	 bang‐sensitivity	 has	 a	 neuronal	 basis,	 we	 used	 electrophysiology	 to	 test	
threshold	 of	 the	 voltage	 stimulus	 given	 to	 the	 fly	 brain	 to	 induce	 a	 seizure.	 	 In	
both	 the	 parabss1	 and	 sda	 backgrounds,	 the	 presence	 of	 Exel6151	 significantly	
reduced	 the	 seizure	 threshold	 compared	 to	 parabss1/+	 and	 sda/+	 controls	
(p<0.05)	(Figure	3.2).	
	
Since	 the	 deficiencies	within	 the	 Exelixis	 collection	 are	well	 characterized	 and	
have	 defined	 breakpoints,	 we	 knew	 that	 there	 are	 four	 genes	 deleted	 within	
Exel6151,	three	of	which	are	moderately	to	highly	expressed	in	neural	tissue.		In	
the	 screen,	we	 targeted	 genes	 that	 are	 highly	 expressed	 in	 the	 nervous	 system	
since	 these	 would	 be	 most	 likely	 to	 have	 a	 direct	 effect	 on	 enhancing	 seizure	
susceptibility.		Therefore,	we	obtained	transposon	insertions	for	the	three	genes	
and	 crossed	 these	 to	 sda.	 	 The	progeny,	which	were	heterozygous	 for	 both	 the	
transposon	 and	 sda,	 were	 tested	 for	 bang‐sensitivity.	 	 The	 progeny	 tested	 are	
heterozygous	 for	 both	 the	 transposon	 and	 sda.	 	 Of	 the	 three	 genes	 tested,	 the	
gene	pumilio	(pum)	was	the	most	effective	at	enhancing	bang‐sensitivity,	though	
the	 other	 two	 genes	 gave	 slight	 enhancement	 as	well	 (Table	 B.10).	 	We	 tested		
 57 
	
	
	
	
	
	
	
	
		
Figure	3.5		Expression	of	pumilio	in	third	instar	larvae	brains.		Confocal	images	of	
pumilio	(green)	and	elav	(red)	show	pumilio	expression	in	most	neurons.		Images	
of	 the	 whole	 brain	 are	 shown	 (A‐C)	 and	 focused	 on	 the	 posterior	 end	 of	 the	
ventral	ganglion	(D‐F).		Scale	bar,	100	μm	(A‐C)	and	10	μm	(D‐E).	
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Figure	 3.6	 	 Expression	 of	 pumilio	 in	 adult	 brains.	 	 Confocal	 images	 of	 pumilio	
(green)	 and	 elav	 (red)	 show	 pumilio	 expression	 in	most	 neurons	 in	 the	whole	
brain	(A‐C)	and	a	higher	magnification	of	the	central	brain	area	(D‐F).		Scale	bar,	
100	μm	(A‐C)	and	10	μm	(D‐E).	
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other	alleles	of	pum	and	found	that	seizure	penetrance	was	enhanced	in	both	the	
sda	and	parabss1	background	by	several	alleles,	though	most	strongly	by	pum01688	
(Figure	 3.3).	 	 Electrophysiology	 tests	 of	 these	 various	pum	 alleles	 showed	 that	
there	 is	 a	 significant	 decrease	 in	 seizure	 threshold	 in	 parabss1/+;	 pum01688	
compared	 to	 controls	 (p<0.05),	 and	while	 the	 threshold	 of	 lines	 that	 use	 other	
pum	alleles	are	decreased	compared	to	control,	 the	difference	was	not	 found	to	
be	significant	(Figure	3.4).	
	
3.4.2	Pumilio	is	expressed	in	larval	and	adult	neurons	
We	decided	to	investigate	the	expression	pattern	of	Pum	protein	in	fly	larvae	and	
adults	 since	 most	 immunohistochemistry	 for	 Pum	 has	 previously	 been	 done	
mainly	 in	 embryos	 and	 adult	 reproductive	 organs	 [23],	 but	 not	 in	many	 other	
structures.	 	 pum	 is	 well	 known	 to	 be	 involved	 in	 processes	 such	 as	 synaptic	
transmission,	dendrite	morphogenesis,	and	other	neurobiological	functions	[15],	
[19],	so	we	examined	Pum	expression	in	the	nervous	system.		We	double	stained	
third	instar	larvae	for	Pum	[23]	and	elav,	a	neuronal	marker,	and	observed	that	
all	cells	that	are	positive	for	cytoplasmic	staining	of	Pum	also	co‐stained	with	elav	
in	their	nuclei	(Figure	3.5),	 indicating	that	Pum	staining	is	exclusively	neuronal,	
supporting	previous	work	done	by	Menon	et	al	[24].		Similarly,	we	stained	adult	
brains	with	 pum	and	 elav	 antibodies	 and	observed	 that	pum	 staining	 occurred	
only	 in	 neuron	 cell	 bodies	 (Fig	 3.6).	 	 We	 also	 double	 stained	 with	 Pum	 and	
Bruchpilot	(Brp),	a	synaptic	marker,	to	show	that	pum	is	located	in	the	cell	bodies	
and	not	 in	 the	neuropil	 (Figure	C.1).	 	Double	staining	with	a	glial	marker,	 repo,	
verified	 that	 pum	 expression	 is	 limited	 to	 neurons	 as	 it	 does	 not	 overlap	with	
repo	(Figure	C.2).			
	
3.4.3	Targeted	knockdown	of	pum	in	neurons	enhances	seizure	susceptibility	
Since	 we	 observed	 that	 Pum	 is	 expressed	 in	 neurons,	 we	 hypothesized	 that	
targeted	knockdown	of	Pum	in	neurons	or	subsets	of	neurons	using	RNAi	could	
produce	 a	 similar	 increase	 in	 seizure	 penetrance	 as	 in	 our	 previous	 tests	with		
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Figure	3.7		Changes	in	seizure	penetrance	due	to	targeted	knockdown	of	pum	in	a	
parabss1/+	background.		The	graph	represents	the	fold	change	in	paralysis	of	flies	
after	 vortexing	 compared	 to	 control	 (parabss1/+).	 	 Pumilio	 is	 knocked	 down	 by	
RNAi	using	specific	GAL4	drivers	in	a	sda	background.		Elav	=	panneural,	VAChT	=	
cholinergic	 neuron,	 cha	 =	 cholinergic	 neurons,	 appl	 =	 panneural,	 tdc	 =	
octopaminergic	 neurons,	 gad1	 =	 GABA‐ergic	 neurons,	 repo	 =	 glia,	 vglut	 =	
glutamatergic	neurons,	slit	=	glia.		N≥20	for	each	genotype.	
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pum	 transposon	 alleles	 and	 deletions.	 	We	 tested	 this	 hypothesis	 in	 two	 bang‐
sensitive	backgrounds	by	crossing	either	parabss1;	pum‐RNAi	or	pum‐RNAi;	sda	to	
various	 GAL4	 lines	 that	 target	 the	 nervous	 system.	 	 The	 candidate	 GAL4	 lines	
targeted	 cholinergic	 neurons,	 Choline	 acetyltransferase	 (Cha)	 and	 Vesicular	
acetylcholine	 transporter	 (VAChT),	 octopaminergic	 neurons,	 tyrosine	
decarboxylase	 (tdc),	 GABAergic	 neurons,	 Glutamic	 acid	 decarboxylase	 (Gad1),	
glutamatergic	neurons,	Vesicular	glutamate	transporter	(VGlut),	all	neurons,	elav	
and	β	amyloid	protein	precursor‐like	(Appl),	and	glia,	reversed	polarity	(repo)	and	
slit	(sli).			
	
We	used	antibody	staining	to	check	the	effectiveness	of	Pum	knockdown	by	RNAi	
by	comparing	control	pum‐RNAi/+	flies	to	elav‐GAL4/+;	pum‐RNAi/+	after	double	
staining	with	Pum	and	elav	antibodies.		In	third	instar	larvae,	the	Pum	labeling	in	
the	ventral	ganglion	is	reduced	(Figure	3.10)	as	well	as	throughout	the	rest	of	the	
larval	 brain	 (Figure	 C.4).	 	 The	 results	 are	 similar	 in	 the	 adult	 brain,	 where	
knockdown	 of	 Pum	 results	 in	 an	 almost	 complete	 lack	 of	 Pum	 staining	 in	 the	
brain	 and	 thoracic	 abdominal	 ganglion	 (Figure	 3.11).	 	 This	 reduction	 of	 Pum	
staining	is	apparently	only	when	we	use	elav‐GAL4	as	the	driver,	since	when	we	
knocked	 down	 Pum	 in	 smaller	 subsets	 of	 neurons	 such	 as	 motor	 neurons,	
glutamatergic	neurons,	cholinergic	neurons,	and	GABA‐ergic	neurons,	we	did	not	
observe	a	change	in	the	staining	pattern	of	Pum	(Figure	C.3).		However,	this	could	
be	an	effect	of	the	driver	strength	at	driving	RNAi	and	a	stronger	GAL4	line	may	
cause	a	clearer	difference	in	Pum	pattern.	
	
All	of	the	GAL4	lines	listed	above	were	crossed	to	parabss1;	pum‐RNAi		and	tested	
for	seizure	behavior,	and	we	found	that	panneural	drivers	(elav	and	Appl)	as	well	
as	 cholinergic	 neuron	 drivers	 (Cha	 and	 VAChT)	 caused	 a	 twofold	 or	 higher	
increase	 in	 bang‐sensitivity	 in	 the	 tested	 adults	 (Figure	 3.7,	 Table	 C.1).	 	 We	
expected	 that	 since	 pum	 alleles	 are	 able	 to	 enhance	 seizure	 susceptibility	 in	
multiple	 lines	 of	 bang‐sensitive	 mutants,	 RNAi	 knockdown	 of	 pum	 should	 be	
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Figure	3.8		Effects	of	pum	knockdown	by	elav‐GAL4	in	a	sda/+	background.		The	
graph	represents	fold	change	in	flies	showing	paralysis	after	vortexing	compared	
to	control	(sda/+)	.		There	is	an	increase	in	paralysis	when	pum	is	knocked	down	
in	 GABA‐ergic	 neurons	 by	 Gad2B‐GAL4,	 and	 to	 a	 lesser	 extent	 in	 cholinergic	
neurons	VAChT‐GAL4	 and	 a	 larger	 increase	 in	 paralysis	 when	 pum	 is	 knocked	
down	by	a	panneural	driver,	elav‐GAL4.		N≥65	for	each	genotype.	
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	Figure	3.9		Seizure	threshold	is	lower	in	adults	with	pum	knockdown	in	neurons.		
parabss1;	 pum‐RNAi	 flies	 were	 crossed	 to	 panneural	 driver	 elav‐GAL4	 and	 the	
seizure	 threshold	 for	 each	 genotype	 was	 determined.	 	 Knockdown	 of	 pum	 in	
neurons	significantly	lowered	the	seizure	threshold	compared	to	control.		p<0.05,	
N≥9	flies	for	both	genotypes.	
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effective	 in	 enhancing	 seizure	 penetrance	 in	 other	 BS	 mutants.	 	 When	 we	
repeated	this	experiment	by	crossing	pum‐RNAi;	sda	to	the	different	drivers,	we	
found	 that	cholinergic,	 similar	 to	 the	previous	experiment,	and	also	GABA‐ergic	
neuron	GAL4	lines	were	also	able	to	 increase	penetrance	of	seizure	(Figure	3.8,	
Table	C.2).	
	
To	 confirm	 that	 the	 increase	 in	 bang‐sensitivity	 penetrance	 was	 due	 to	 an	
increase	 in	 neuronal	 excitability,	 we	 measured	 the	 seizure	 threshold	 of	 the	
parabss1,	 elav‐GAL4/+;	 pum‐RNAi/+	 flies,	 which	 had	 given	 the	 strongest	
enhancement	 phenotype	 in	 the	 vortex	 testing.	 	 We	 found	 that	 the	 seizure	
threshold	 for	 this	genotype	 is	 significantly	 lower	 in	parabss1,	elav‐GAL4/+;	pum‐
RNAi/+	 flies	 (7.56±0.53V)	 compared	 to	 the	 control,	 parabss1/+;	 pum‐RNAi/+	
(10.58±1.22V),	p<0.05	(Figure	3.9,	Table	C.3).	 	These	recordings,	along	with	the	
behavioral	testing,	confirms	that	knockdown	of	Pum	in	neurons	does	enhance	the	
penetrance	of	seizure	behavior.	 	Specific	knockdown	in	cholinergic	neurons	also	
produces	a	behavioral	effect,	though	we	have	not	measured	seizure	thresholds	in	
these	flies.	
	
From	behavior	testing,	we	observed	that	targeting	Pum	knockdown	through	the	
cholinergic	 neuron	 driver	 VAChT‐GAL4	 was	 also	 effective	 at	 increasing	 the	
penetrance	 of	 bang‐sensitivity	 in	 the	parabss1	 and	 sda	 backgrounds	 (Figure	 3.8,	
Figure	 3.9).	 	 One	 possibility	 for	 this	 phenotype	 is	 that	 cholinergic	 neurons	
comprise	a	large	subset	of	the	cells	stained	by	Pum,	so	we	used	antibody	staining	
to	determine	the	pattern	of	VAChT‐positive	cells	compared	to	Pum‐positive	cells.		
We	 constructed	 an	 nls‐GFP;	VAChT‐GAL4	 stock	 to	 express	 GFP	 in	 the	 nuclei	 of	
cells	 that	 express	VAChT	 and	 performed	double	 antibody	 staining	 against	 Pum	
and	GFP	in	these	flies.		In	third	instar	larvae,	we	observed	in	the	ventral	ganglion,	
many	 VAChT‐expressing	 nuclei	 are	 found	 within	 cells	 with	 Pum	 cytoplasmic	
staining	(Figure	3.12	D‐F)	and	a	smaller	number	of	VAChT‐expressing	nuclei	are	
found	in	the	brain	lobes	(Figure	3.12	A‐C).		In	adults,	we	also	observed	that	there	
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Figure	3.10	Knockdown	of	pum	in	neurons	of	third	instar	larvae.		Knockdown	of	
pumilio	in	neurons	using	RNAi	and	elav‐GAL4	driver.		Confocal	images	of	third	
instar	larvae	brains,	specifically	ventral	ganglion,	stained	with	pumilio	antibody	
and	elav	antibody.		Scale	bar,	50	μm.		
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Figure	3.11		Knockdown	of	pum	in	neurons	of	adult	brains.		Maximum	projection	
of	confocal	z‐series	of	adult	brains	stained	with	pumilio	and	elav.	 	Scale	bar,	50	
μm.	
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are	many	nuclei	 expressing	VAChT	 in	 cells	 that	 also	have	Pum	staining	 (Figure	
3.13),	suggesting	that	cholinergic	neurons	comprise	a	significant	fraction	of	Pum‐
positive	neurons.		
	
3.4.4	 Disruption	 of	 pumilio	 expression	 during	 the	 entire	 life	 cycle	 causes	
enhancement	of	neuronal	excitability	
Thus	 far	 all	 of	 our	 tests	 have	 used	 alleles	 of	 pum	 or	 RNAi	 knockdown	 of	 Pum	
throughout	the	entire	life	cycle	of	the	fly.		Could	Pum	knockdown	in	specific	stage	
of	the	life	cycle	cause	enhancement	of	bang‐sensitivity?		 	To	test	this,	we	used	a	
GAL80ts	line	recombined	with	pum‐RNAi	to	perform	knockdown	of	Pum	during	
specific	 stages	 of	 the	 fly	 life	 cycle.	 	We	 crossed	 this	 line	 to	 elav‐GAL4,	 sda	 and	
raised	 the	progeny	at	 the	 restrictive	 temperature	during	specific	periods	of	 the	
life	 cycle.	 	 GAL4	 is	 active	 only	 at	 the	 restrictive	 temperature,	 so	 knockdown	of	
Pum	occurs	only	during	this	time.	 	 In	this	 initial	 test,	all	eggs	were	laid	at	25°C.		
One	set	of	flies	was	placed	at	29°C	during	all	larval	stages,	another	set	was	placed	
at	29°C	from	pupation	to	adulthood,	and	another	set	of	flies	were	raised	at	29°C	
from	the	 first	 instar	stage	and	onwards.	 	We	collected	the	 flies	and	tested	them	
for	bang‐sensitivity,	and	observed	that	only	flies	raised	for	their	entire	life	cycle	
at	 the	 restrictive	 temperature	 showed	 a	 large	 increase	 in	 seizure	 penetrance	
(Figure	3.14).		Those	raised	at	the	restrictive	temperature	through	pupation	and	
eclosion	 showed	 a	 slight	 increase	 in	 bang‐sensitivity.	 	 Pum	 expression	 during	
pupation	is	important	to	normal	development,	as	overexpression	of	Pum	during	
this	period	can	cause	lethality	(Table	C.4).		Repeating	this	test	with	smaller	time	
windows	may	help	to	refine	the	critical	period	suggested	by	these	results. 
 
2.5 Discussion 
In	our	study,	we	have	shown	that	Pum	is	expressed	in	neurons	in	the	larval	and	
adult	nervous	system.		Specifically,	Pum	is	found	in	most	neurons	as	shown	by	its	
overlap	with	 elav,	 a	 well‐known	 neural	marker,	 and	 knockdown	 of	 Pum	 using		
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Figure	 3.12	 	 Localization	 of	 Pum	 in	 cholinergic	 neurons	 in	 third	 instar	 larval	
brains.	 	 Anti‐GFP	 and	 anti‐Pum	 staining	 with	 VAChT‐GAL4	 driving	 a	 nuclear	
localized	 GFP	 in	 the	 larval	 brain,	 specifically	 the	 lobe	 (A‐C)	 and	 the	 ventral	
ganglion	(D‐F).		Scale	bar	is	100	μm.		
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RNAi	using	a	panneural	driver	was	able	 to	abolish	much	of	 the	Pum	staining	 in	
both	 larval	 and	 adult	 brains.	 	 Knockdown	 of	 Pum	 using	 drivers	 that	 targeted	
subsets	of	neurons	did	not	noticeably	remove	Pum	staining.		One	explanation	for	
this	 is	 that	 different	 GAL4	 drivers	 have	 different	 levels	 of	 effectiveness.	 	 For	
example,	 we	 used	 two	 different	 elav‐GAL4	 lines	 (C155	 and	 3A4)	 in	 our	
experiments,	 and	C155	had	a	much	 stronger	 effect	 on	expression	and	behavior	
than	3A4.	 	 It	 is	possible	 that	the	GAL4	 lines	we	used	to	target	neuronal	subsets	
were	not	able	to	drive	pum‐RNAi	effectively.	
	
Earlier	studies	in	adult	Pum	expression	indicated	that	the	protein	was	expressed	
throughout	 the	 central	 nervous	 system,	 especially	 in	 the	 Kenyon	 cells	 of	 the	
mushroom	 bodies	 [18].	 	 We	 did	 observe	 increased	 staining	 ventral	 to	 the	
mushroom	bodies,	between	the	antennal	lobes	and	mushroom	bodies.		However,	
the	Kenyon	cells	are	 located	more	dorsal	 to	 the	mushroom	bodies	 [25]	and	are	
unlikely	to	be	the	area	with	increased	Pum	staining	in	our	figures.	 	One	unusual	
aspect	of	the	cells	we	stained	is	that	while	Pum	staining	is	very	high,	elav	staining	
in	these	cells	is	also	lower	than	that	of	surrounding	cells.		As	elav	is	not	expressed	
in	 neuroblasts	 or	 earlier	 stages,	 but	 does	 appear	 in	 all	 neurons,	 a	 possible	
explanation	 may	 be	 that	 these	 cells	 are	 in	 the	 process	 of	 differentiating	 into	
neurons.		While	cell	division	and	differentiation	in	the	adult	brain	is	rare,	recent	
work	 has	 shown	 that	 there	 is	 indeed	 cell	 proliferation	 in	 the	 adult	 fly	 brain.		
These	cells	are	also	located	around	the	area	of	the	antennal	lobe	[26].	
	
From	 a	 deficiency	 screen,	 we	 identified	 pum	 as	 an	 enhancer	 of	 bang‐sensitive	
behavior.	 	 The	 deficiency	 that	 deleted	 pum	 was	 able	 to	 enhance	 the	 seizure	
penetrance	 in	 three	different	bang‐sensitive	mutants,	parabss1,	 sda,	 and	eas	 that	
are	 known	 to	 have	 different	 seizure	 thresholds	 but	 cause	 very	 similar	 seizure‐
paralysis‐seizure	 phenotypes	 [27].	 	 parabss1	 is	 a	 gain‐of‐function	 mutation	 in	 a	
voltage‐gated	 Na+	 channel	 that	 causes	 a	 change	 in	 Na+	 inactivation	 [28].	 	 sda	
encodes	a	mutation	 in	an	aminopeptidase	 that	 increases	persistent	Na+	current		
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Figure	3.13		Localization	of	Pum	in	cholinergic	neurons	in	adult	brains.		Anti‐GFP	
and	 anti‐Pum	 double	 labeling	 of	 VaCHT‐GAL4	 driving	 nuclear	 localized	 GFP.		
Scale	bar	is	100	μm.	
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[29].		The	mutation	in	eas,	which	encodes	an	ethanolamine	kinase,	is	believed	to	
alter	membrane	phospholipid	composition	that	causes	an	excitability	defect	[30].		
Because	the	three	different	bang‐sensitive	mutations	are	very	different	and	cause	
seizures	 through	 different	 methods,	 the	 enhancement	 of	 seizure	 penetrance	
caused	by	pum	 is	most	 likely	 due	 to	 a	 general	 increase	 in	neuronal	 excitability	
instead	of	being	specific	 to	a	defect	caused	by	one	bang‐sensitive	mutant.	 	Flies	
that	are	mutant	for	pum	do	not	have	seizures	themselves.		However,	recent	work	
in	 mice	 has	 shown	 that	 those	 carrying	 a	 specific	 allele	 of	 pum2,	 the	 mouse	
homolog	of	Drosophila	pum,	show	spontaneous	seizures	due	to	handling	and	have	
lower	 seizure	 thresholds	 in	 response	 to	 convulsants	 [31].	 	 This	 suggests	 that	
there	may	 be	 a	 closer	 link	 between	pum	 and	 seizure	 behavior	 than	 previously	
thought.	
	
Although	Pum	is	expressed	in	most	and	perhaps	all	neurons,	it	is	possible	that	the	
enhancement	of	seizure	susceptibility	is	due	to	lack	of	Pum	in	a	specific	subset	of	
neurons.	 	 Studies	 using	 pumbem,	 an	 allele	 of	 pum,	 showed	 that	 Pum	 is	 able	 to	
regulate	 Na+	 current	 in	 specific	 motoneurons,	 and	 the	 pumbem	 allele	 is	 able	 to	
increase	 Na+	 current	 which	 would	 lead	 to	 greater	 neuronal	 excitability	 [21].		
Therefore,	 it	 had	 been	 believed	 that	 the	 primary	 cause	 of	 increased	 neuronal	
excitability	due	to	pum	mutations	is	due	to	defects	in	motor	neurons.	 	However,	
we	 found	 that	 knockdown	 of	 Pum	 in	 glutamatergic	 neurons,	 which	 releases	
glutamate	at	the	neuromuscular	 junction	(NMJ),	 in	a	parabss1	or	sda	background	
did	not	enhance	bang‐sensitivity	as	much	as	other	types	of	neurons.		Instead,	the	
neurons	 that	 produced	 the	 greatest	 effect	 on	BS	 behavior	were	 the	 cholinergic	
neurons	 in	 the	 case	 of	 the	 parabss1/+	 background.	 	 A	 previous	 study	 on	 the	
vesicular	 acetylcholinergic	 transporter	 (VAChT)	 showed	 the	 defects	 in	 VAChT	
caused	 defects	 in	 the	 giant	 fiber	 pathway,	 most	 likely	 due	 to	 reduction	 in	
acetylcholine	 levels	 at	 the	giant	 fiber	 synapses	 [32].	 	 Studies	 in	mice	 show	 that	
VAChT	 knockouts	 have	 spontaneous	 release	 of	 neurotransmitters	 at	 the	
neuromuscular	 junction	 and	 also	 have	 defective	 NMJ	 development	 [33].	 	 It	 is	
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Figure	3.14		Effects	of	knockdown	of	pumilio	at	various	stages	of	fly	life	cycle	on	
bang‐sensitivity	penetrance.		Knockdown	of	pum	was	done	by	crossing	GAL80ts,	
pum‐RNAi	 flies	 to	 elav‐GAL4,	 sda	 and	 raising	 the	 elav‐GAL4/+;	 GAL80ts,	 pum‐
RNAi/+;	sda/+	progeny	at	29°C	during	the	indicated	developmental	stages.		Once	
the	flies	reached	adulthood,	they	were	tested	for	bang‐sensitivity.		N≥20	for	each	
category.	
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possible	 that	pum	 has	 a	 role	 in	 normal	 development	 of	 the	 NMJ	 in	 cholinergic	
neurons,	 and	 that	 lack	 of	 Pum	 leads	 to	 defects	 that	 cause	 increased	 neuronal	
excitability.			
	
In	 the	sda/+	background,	while	knockdown	of	Pum	in	cholinergic	neurons	does	
enhance	the	BS	behavior,	the	greatest	change	is	caused	by	knockdown	of	Pum	in	
GABAergic	 neurons.	 	 There	 is	 evidence	 that	 reduced	 GABAergic	 synaptic	
transmission	and	the	resulting	lack	of	 inhibition	can	lead	to	seizures,	which	has	
been	shown	both	in	human	epilepsy	caused	by	mutations	in	genes	encoding	the	
GABAA	receptor	subunits,	GABRA1	and	GABRG2,	and	in	the	Drosophila	kazachoc	
(kcc)	mutant	 [34],	 [35].	 	Analysis	 of	 the	kcc	mutant	 suggested	 that	 influence	of	
altered	 GABAergic	 signaling	 occurs	 in	 the	 mushroom	 bodies	 and	 takes	 place	
during	the	late	pupal‐early	adult	period	[35].		Interestingly,	our	results	show	that	
normal	Pum	expression	during	the	late	pupal‐early	adult	period	is	also	important	
for	survival,	as	overexpression	of	Pum	during	this	stage	lowers	the	survival	rate	
to	adulthood.		Since	the	effect	of	GABAergic	neuron‐targeted	Pum	knockdown	in	
seizure	behavior	 is	 limited	 to	 sda,	we	hope	 to	 explore	 the	 role	of	 sda	 in	neural	
development	during	these	pupal	stages.	
	
We	 have	 shown	 in	 this	 study	 that	 mutations	 of	 pum	 in	 flies	 cause	 a	 strong	
enhancement	in	BS	seizures.	 	Since	Pum	is	expressed	in	neurons,	knockdown	of	
Pum	 using	 neural	 drivers	 also	 replicates	 this	 effect,	 though	 most	 potently	 by	
panneural	 drivers,	 and	 almost	 as	 well	 by	 cholinergic,	 and	 GABAergic	 neuron	
drivers.	 	 Conditional	 knockdown	of	 Pum	during	 specific	 stages	 of	 development	
showed	 that	 a	 reduction	 of	 Pum	must	 occur	 both	 in	 larval	 and	 through	 pupal	
stages	 in	 order	 for	 the	 seizure	 enhancement	 to	 occur.	 	 Also,	 there	 is	 a	 period	
between	third	 instar	and	pupal	stages	that	 is	 important	 for	development.	 	With	
this	 new	 knowledge	 about	 pum	 and	 continued	 refinement	 of	 experiments	
described	in	this	study,	we	will	be	able	to	narrow	down	the	critical	location	and	
time	window	of	Pum	involvement	in	neuronal	excitability.		
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CHAPTER	4	
SUMMARY	AND	FUTURE	DIRECTIONS	
	
4.1		Brief	overview	
In	 the	previous	chapters,	 I	have	discussed	a	behavioral	genetic	screen	 in	which	
we	 looked	 for	 genes	 that	may	 help	 our	 understanding	 of	 neuronal	 excitability,	
and	 by	 extension,	 the	 underlying	 mechanisms	 and	 genetics	 behind	
epileptogenesis.	 	 Following	 this,	 I	 discussed	 our	 analysis	 of	 one	 of	 the	 genes,	
pumilio	(pum)	that	was	found	in	this	screen.			
	
4.2	 	 	 Deficiency	 screening	 for	 enhancers	 of	 the	 bang‐sensitive	 mutant	
slamdance	
Since	research	 in	 the	genetic	basis	of	epilepsy	 is	moving	 towards	 large	scale	or	
genome	wide	studies	to	identify	genes	associated	with	epilepsy	[1],	we	hoped	to	
use	 the	 tools	 available	 to	Drosophila	 to	 efficiently	 screen	 for	 such	 genes	 in	 fly	
seizure	mutants.	 	The	goal	of	this	project	was	to	find	new	genes,	previously	not	
implicated	 as	 being	 involved	 in	 seizure	 behaviors	 or	 neuronal	 excitability.	 	We	
performed	an	enhancer	screen	using	the	seizure	phenotype	of	the	bang‐sensitive	
mutant	slamdance.			
	
4.2.1		Eleven	candidate	enhancers	of	bang‐sensitivity	
We	 screened	 chromosome	 3R	 for	 enhancers	 of	 seizure	 susceptibility	 using	 an	
Exelixis	deficiency	kit.		Out	of	the	15	Exelixis	deficiencies	that	enhanced	the	bang‐
sensitivity	of	 sda	 heterozygotes	we	discovered	11	 candidate	 genes	with	known	
functions.		Three	of	the	eleven	genes	are	known	to	be	involved	in	nervous	system	
development:	Tetraspanin	86D	(Tsp86D),	CG31140,	and	48	related	2	(fer2).		Two	
have	 functions	 in	 the	secretory	pathway:	yata	 and	Sorting	nexin	3	 (Snx3).	 	Two	
encode	O2	and	NO	sensors.		Guanylyl	cyclase	β	encodes	an	NO	sensor	and	Similar	
(Sima)	 is	 an	 oxygen	 sensor.	 	 Three	 genes	 encode	 proteins	 involved	 in	
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translational	control:	Akt,	pum,	and	CG18616.		Only	two	of	eleven	genes,	pum	and	
CG9467,	had	previously	been	associated	with	enhancing	neuronal	excitability	or	
having	homology	to	epilepsy	genes.			
	
4.2.2		Searching	for	interactors	of	sda	
Ten	out	of	the	eleven	candidate	enhancer	genes	increased	BS	seizure	penetrance	
in	both	the	heterozygous	parabss1	and	sda	background.		This	was	shown	indirectly	
by	 testing	 the	Exelixis	deficiencies	 that	 contained	 these	genes	 and	 showing	 the	
general	 enhancement	 to	 both	 BS	 mutants.	 	 One	 of	 the	 genes	 causes	 seizure	
enhancement	 specific	 to	 sda	 and	may	 encode	 a	product	 that	 is	 an	 interactor	of	
only	 sda.	 	 Two	deficiencies	 tested	 in	 this	 screen	 caused	 synthetic	 lethality	with	
sda	but	not	other	bang‐sensitive	lines.	 	Though	we	have	not	yet	determined	the	
genes	underlying	the	synthetic	lethality,	we	hope	to	use	these	deficiencies	to	find	
possible	interactors	of	sda.	
	
4.3	 	 pumilio	 is	 required	 during	 several	 development	 stages	 for	 normal	
neuronal	excitability	
We	 explored	 the	 role	 of	 pum	 in	 enhancing	 seizure	 susceptibility	 after	 it	 was	
discovered	in	the	deficiency	screen.		Though	other	work	had	shown	that	pum	was	
involved	 in	neuronal	excitability	and	growth	of	 the	neuromuscular	 junction	[2],		
[3],	they	did	not	show	an	actual	change	in	behavior.		We	showed	in	chapter	3	that	
mutations	 in	pum,	or	knockdown	of	Pum	by	RNAi,	 can	enhance	 the	duration	or	
severity	of	seizure	behavior.		
	
4.3.1		Pumilio	is	expressed	in	neurons	in		larval	and	adult	central	nervous	systems	
We	 were	 able	 to	 show	 by	 using	 Pum	 and	 elav	 antibody	 staining	 that	 Pum	 is	
expressed	 in	most	 if	 not	 all	 neurons.	 	We	 also	 showed	 that	 Pum	 expression	 is	
predominantly	 in	 neurons,	 as	 knocking	 down	 Pum	 using	 RNAi	 targeted	 to	
neurons	 abolishes	 most	 Pum	 expression.	 	 This	 allowed	 us	 to	 perform	 further	
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studies	using	elav‐GAL4	 to	 study	 the	effects	of	 conditional	Pum	knockdowns	at	
specific	points	in	the	life	cycle.			
	
4.3.2	 	 Decreasing	 levels	 of	 Pum	 through	 mutant	 alleles	 or	 RNAi	 knockdown	
enhances	bang‐sensitive	behavior	
Mutations	 in	pum	 can	 cause	enhancement	of	BS	 seizure	penetrance	 in	both	 the	
sda	 and	 parabss1	 backgrounds.	 	 Knockdown	 of	 Pum	 using	 RNAi	 targeted	 to	
neurons	in	a	BS	background	also	caused	a	higher	penetrance	of	the	BS	phenotype.		
We	confirmed	these	findings	using	electrophysiology,	showing	that	when	Pum	is	
reduced	either	by	mutation	or	RNAi,	the	voltage	of	stimulus	required	to	cause	a	
seizure	 response	 is	 significantly	 lower	 than	 in	 control	 flies.	 	 These	 results	
provided	behavioral	evidence	 that	pum	 is	 involved	 in	seizure	susceptibility	and	
neuronal	 excitability.	 	 Since	 targeting	 neurons	 caused	 the	 enhancement,	 it	 is	
likely	that	the	role	of	Pum	in	enhancing	BS	seizures	 is	due	to	changes	 in	neural	
development	and	not	due	to	early	developmental	roles	in	germ	cell	maintenance	
and	axis	patterning.	
		
4.3.3	 	Pum	reduction	in	GABAergic	or	cholinergic	neurons	is	effective	in	enhancing	
bang‐sensitivity	
We	 tested	 Pum	knockdown	 in	 various	 subsets	 of	 neurons	 to	 determine	 if	 Pum	
function	 in	 neuronal	 excitability	 is	 limited	 to	 specific	 neurons.	 	We	 discovered	
that	 in	both	parabss1	 and	 sda,	 knockdown	of	Pum	 in	cholinergic	neurons	caused	
enhancement	 of	 BS	 seizures.	 	 In	 the	 sda	 background,	 knockdown	 of	 Pum	 in	
GABAergic	neurons	had	an	even	greater	effect	on	 seizure	behavior.	 	This	 is	 the	
first	 example	 showing	 that	 Pum	 expression	 in	 specifically	 cholinergic	 and	
GABAergic	neurons	is	needed	for	normal	neuronal	excitability.	
	
4.3.4	 	Enhancement	 of	BS	 phenotype	 only	 occurs	when	 there	 is	 Pum	 knockdown	
through	larval	and	pupal	stages	
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We	 initially	 thought	 that	 since	seizure	behavior	 is	only	apparent	 in	adult	bang‐
sensitive	mutants	and	not	 in	 larvae,	 that	 loss	of	Pum	in	 the	development	of	 the	
adult	brain	(during	the	pupal	stage)	would	be	sufficient	to	cause	enhancement	in	
bang‐sensitive	behavior.		However,	we	found	that	knockdown	of	Pum	in	neurons	
needs	to	occur	through	the	majority	of	the	life	cycle	post	hatching	in	order	for	the	
BS	seizure	enhancement	to	occur.		It	is	likely	that	defects	in	neural	development	
in	larval	stages	are	exacerbated	by	further	effects	of	Pum	knockdown	during	the	
development	 of	 the	 adult	 nervous	 system,	 leading	 to	 a	 large	 increase	 in	 BS	
seizure	penetrance.	
	
4.4		Future	directions	
4.4.1		Deficiency	screening	for	enhancers	and	suppressors	of	bang‐sensitivity	
As	with	most	genetic	screens,	 the	screen	 itself	 is	only	the	very	beginning	of	 the	
project.	 	 Our	 screen	 and	 subsequent	 study	 of	 pum	 leaves	 us	 with	 other	 9	
candidate	enhancer	genes	of	neuronal	excitability.	 	The	next	 steps	would	be	an	
analysis	of	each	of	these	genes	similar	to	what	we	have	done	for	pum.		We	would	
need	 to	ascertain	where	 these	genes	are	expressed,	what	developmental	 stages	
are	 critical	 for	 the	 enhancer	 phenotype,	 and	 how	 each	 gene	 contributes	 to	 the	
seizure	phenotype.		We	will	also	need	to	investigate	how	the	genes	affect	the	sda	
mutant	that	leads	to	the	seizure	enhancement.	
	
Overall,	our	screen	only	covered	a	small	portion	of	the	Drosophila	genome.		Since	
the	 screen	 was	 successful	 for	 discovering	 enhancer	 genes,	 a	 more	 expansive	
screen	 using	 larger	 sets	 of	 different	 deficiency	 kits	would	 allow	 us	 to	 discover	
more	enhancer	genes	and	potential	interactors	of	sda.		If	we	continue	the	screen	
with	the	restriction	of	searching	for	genes	with	expression	in	the	nervous	system,	
we	may	miss	some	genes,	but	since	the	sda	phenotype	is	caused	by	altered	ionic	
current	 in	neurons,	 it	 is	reasonable	to	restrict	our	search	to	genes	expressed	 in	
the	nervous	system.	
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4.4.2		pumilio	and	its	roles	in	neuronal	excitability	
We	have	only	begun	to	narrow	down	the	windows	of	Pum	function	in	relation	to	
enhancement	of	bang‐sensitivity,	both	spatially	and	temporally.	 	While	we	have	
found	that	Pum	expression	in	larval	stages	and	in	pupal	stages	are	needed	for	the	
enhancement	of	BS	seizures,	we	do	not	know	if	this	means	that	Pum	knockdown	
must	 take	place	over	 this	 entire	period,	 if	 there	 is	 one	 time	period,	 or	multiple	
developmental	 stages.	 	 Further	 testing	 can	 help	 us	 to	 figure	 these	 critical	
developmental	 stages,	 and	 this	 knowledge	 can	 subsequently	 be	 used	 to	 test	
specific	 neuronal	 subsets,	 such	 as	 cholinergic	 and	 GABAergic	 neurons.	 	 Since	
these	represent	a	population	of	excitatory	neurons	and	a	population	of	inhibitory	
neurons,	 respectively,	 it	 is	 possible	 that	 Pum	 functions	 through	more	 than	 one	
mechanism	or	pathway	in	order	to	cause	the	enhancement	of	BS	behavior.	
	
Pum	 most	 likely	 regulates	 a	 large	 number	 of	 genes,	 as	 revealed	 by	 a	 screen	
mRNAs	with	Pum	binding	sequences[4],	 though	a	screen	 for	synaptic	 targets	of	
Pum	 only	 resulted	 in	 a	 small	 number	 of	 genes	 [5].	 	 It	 is	 possible	 that	 some	 of	
these	 synaptic	 targets	 of	 Pum	 also	 regulate	 neuronal	 excitability,	 and	 that	
behavior	 testing	 using	 the	 same	methods	 as	 described	 in	 the	 deficiency	 screen	
can	be	used	to	determine	this.	 	We	hypothesize	that	 testing	seizure	behavior	 in	
genes	that	are	targets	of	Pum	may	allow	us	to	uncover	the	process	by	which	Pum	
is	able	to	enhance	BS	behavior.			
	
It	 is	our	belief	 that	 that	 this	work	will	 contribute	 to	 the	 role	of	Drosophila	 as	 a	
model	 system	 of	 epilepsy	 by	 expanding	 the	 available	 repertoire	 and	
understanding	of	neuronal	excitability	mutations.	
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APPENDIX A 
 
 
	
	
	
	
	
Table	A.1	
Preliminary	Exelixis	deficiency	screen	results	
	
Deficiency	
Chromosomal	
Location	 Effect	on	sda	
#	of	genes	
deleted	
	
Likely	“enhancer”
Df(3R)Exel6141	 82B3‐82C4	 enhance	 10	
	
unknown	
Df(3R)Exel6202	 96D1‐96E2	 enhance	 33	
	
unknown	
Df(3R)Exel6140	 82A3‐82A5	 enhance	 11	
	
complexin	
Df(3R)Exel6152	 85C11‐85D2	 enhance	 4	
	
pumilio	
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APPENDIX B 
SUPPLEMENTARY MATERIAL FOR CHAPTER 2 
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Table	B.1	
Complete	list	of	Bloomington	fly	stocks	used	
	
Bloomington	Stock	
Number	 Genotype	
458	 P{w+mW.hs=GawB}elavC155	
507	 gl2	e4	
1799	 w*;	P{w+mC=GAL4‐Hsp70.PB}89‐2‐1	
1931	 Df(3R)by10,	red1	e1/TM3,	Sb1	Ser1	
3125	 Df(3L)fz‐GS1a,	P{w+tAR	ry+t7.2AR=wAR}66E/TM3,	Sb1	
4381	 bw1;	RopG27	st1/TM6B,	Tb+	
4775	 w1118;	P{w+mC=UAS‐GFP.nls}14	
4776	 w1118;	P{w+mC=UAS‐GFP.nls}8	
5458	 w*;	pros17/TM6B,	Tb1	
5905	 w1118	
6190	 svp1/TM3,	Sb1	Ser1	
6326	 w1118	
6782	 w*;	P{w+mC=lacW}pumbem/TM6	
6793	 w*;	P{w+mC=Cha‐GAL4.7.4}19B	P{w+mC=UAS‐GFP.S65T}T2	
6798	 w1118;	P{w+mC=Cha‐GAL4.7.4}19B/CyO,	P{ry+t7.2=sevRas1.V12}FK1	
6800	 w*;	P{w+mC=nrv2‐GAL4.S}3	
7010	 w1118;	P{w+mC=Ddc‐GAL4.L}4.3D	
7017	 w*;	P{w+mC=tubP‐GAL80ts}2/TM2	
7019	 w*;	P{w+mC=tubP‐GAL80ts}20;	TM2/TM6B,	Tb1	
7108	 w*;	P{w+mC=tubP‐GAL80ts}10;	TM2/TM6B,	Tb1	
7347	 y1	w67c23;	P{y+t7.7=Mae‐UAS.6.11}nosUY4741	
7415	 w1118;	P{w+m*=GAL4}repo/TM3,	Sb1	
8760	 w*;	P{w+mC=GAL4‐elav.L}3	
8848	 w*;	P{w+mC=ple‐GAL4.F}3	
8968	 w1118;	Df(3R)ED5516,	P{w+mW.Scer\FRT.hs3=3'.RS5+3.3'}ED5516/TM6C,	cu1	Sb1	
9086	 w1118;	Df(3R)ED5591,	P{w+mW.Scer\FRT.hs3=3'.RS5+3.3'}ED5591/TM6C,	cu1	Sb1	
9200	 w1118;	Df(3R)ED5220,	P{w+mW.Scer\FRT.hs3=3'.RS5+3.3'}ED5220/TM3,	Ser1	
9206	 w1118;	Df(3R)ED5573,	P{w+mW.Scer\FRT.hs3=3'.RS5+3.3'}ED5573/TM3,	Ser1	
9227	 w1118;	Df(3R)ED5428,	P{w+mW.Scer\FRT.hs3=3'.RS5+3.3'}ED5428/TM6C,	cu1	Sb1	
9313	 w*;	P{w+mC=Tdc2‐GAL4.C}2	
9338	 w1118;	Df(3R)ED5296,	P{w+mW.Scer\FRT.hs3=3'.RS5+3.3'}ED5296/TM6C,	cu1	Sb1	
9482	 w1118;	Df(3R)ED10642,	P{w+mW.Scer\FRT.hs3=3'.RS5+3.3'}ED10642/TM6C,	cu1	Sb1	
9516	 Canton‐S‐iso3A	
9580	 w*;	P{w+mC=GAL4‐sli.S}3	
9622	 w1118;	Df(3R)BSC196/TM6B,	Tb+	
9699	 w1118;	Df(3R)BSC222/TM6B,	Tb+	
10344	 ry506	P{ry+t7.2=PZ}sda03884,	l(3)0388403884/TM3,	ryRK	Sb1	Ser1	
10967	 w1118;	PBac{w+mC=PB}CG2747c02682/TM6B,	Tb1	
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11544	 P{ry+t7.2=PZ}pum01688	ry506/TM3,	ryRK	Sb1	Ser1	
11590	 P{ry+t7.2=PZ}CtBP03463	ry506/TM3,	ryRK	Sb1	Ser1	
11604	 ry506	P{ry+t7.2=PZ}repo03702/TM3,	ryRK	Sb1	Ser1	
11627	 ry506	P{ry+t7.2=PZ}Akt104226/TM3,	ryRK	Sb1	Ser1	
11720	 P{ry+t7.2=PZ}eIF‐4E07238	ry506/TM3,	ryRK	Sb1	Ser1	
12128	 y1	w*;	P{w+mC=lacW}Vha55j2E9/TM3,	Sb1	
12146	 y1	w*;	P{w+mC=lacW}l(3)j5C7j5C7/TM6B,	Tb1	
13221	 y1	w67c23;	P{y+mDint2	wBR.E.BR=SUPor‐P}Teh1KG02438	
13221	 y1	w67c23;	P{y+mDint2	wBR.E.BR=SUPor‐P}Teh1KG02438	
13427	 y1	w67c23;	ry506	P{y+mDint2	wBR.E.BR=SUPor‐P}CG31140KG01345	
15013	 y1	w67c23;	P{w+mC	y+mDint2=EPgy2}CG6439EY00276	
15077	 y1	w67c23;	P{w+mC	y+mDint2=EPgy2}kayEY01644/TM3,	Sb1	Ser1	
15221	
y1;	ry506	P{y+mDint2 wBR.E.BR=SUPor‐P}Gycbeta100BKG09937 stopsKG09937/TM3,	Sb1
Ser1	
15965	 y1	w67c23;	P{w+mC	y+mDint2=EPgy2}CG18005EY06611	
16029	 y1	w1118;	PBac{w+mC=5HPw+}Fas1A071/TM3,	Sb1	Ser1	
16364	 y1	w67c23;	P{w+mC	y+mDint2=EPgy2}Glut4EFEY03156	
16668	 y1	w67c23;	P{w+mC	y+mDint2=EPgy2}CG6359EY05688	
16690	 y1	w67c23;	P{w+mC	y+mDint2=EPgy2}nonA‐lEY05999	
17837	 w1118;	PBac{w+mC=RB}CG6574e00293	
18407	 w1118;	PBac{w+mC=WH}CG7918f01078/TM6B,	Tb1	
18502	 w1118;	PBac{w+mC=WH}Ank2f02001	CG32373f02001/TM6B,	Tb1	
19012	 w1118;	PBac{w+mC=WH}CG10326f06814	CG10324f06814	
20472	 y1	w67c23;	P{y+t7.7	w+mC=wHy}cpxDG23508	
20582	 y1	w67c23;	P{y+t7.7	w+mC=wHy}Mcm5DG12108	
20714	 y1	w67c23;	P{w+mC	y+mDint2=EPgy2}CG5903EY11938	
21042	 y1	w67c23;	P{y+t7.7	w+mC=wHy}pumDG05207/TM3,	Sb1	Ser1	
21042	 y1	w67c23;	P{y+t7.7	w+mC=wHy}pumDG05207/TM3,	Sb1	Ser1	
21214	 y1	w67c23;	P{w+mC	y+mDint2=EPgy2}kokoEY16502	
22559	 y1	w67c23;	P{w+mC	y+mDint2=EPgy2}SelREY22443	
22750	 y1	w67c23;	Mi{ET1}cpxMB00267	
23491	 w1118;	Mi{ET1}hugMB02782	
23750	 y1	w67c23;	Mi{ET1}CG31140MB01635/TM3,	Sb1	Ser1	
24365	 w1118;	Df(2L)BSC341/CyO	
24635	 P{w+mC=VGlut‐GAL4.D}1,	w*	
24635	 P{VGlut‐GAL4.D}1,	w*	
24976	 w1118;	Df(3R)BSC472/TM6C,	Sb1	cu1	
24981	 w1118;	Df(3R)BSC477/TM6C,	Sb1	cu1	
24994	 w1118;	Df(3R)BSC490/TM6C,	Sb1	cu1	
25006	 w1118;	Df(3R)BSC502/TM6C,	Sb1	cu1	
25010	 w1118;	Df(3R)BSC506/TM6C,	Sb1	cu1	
25013	 w1118;	Df(3R)BSC509/TM6C,	Sb1	cu1	
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25057	 w1118;	Df(3R)BSC529/TM6C,	Sb1	
25126	 w1118;	Df(3R)BSC568/TM6C,	Sb1	
25275	 w1118;	Mi{ET1}CG7675MB07646/TM6C,	Sb1	
25374	 y1	w*;	P{Act5C‐GAL4‐w}E1/CyO	
25374	 y1	w*;	P{Act5C‐GAL4‐w}E1/CyO	
25681	 y1	w*;	P{w+mC=npf‐GAL4.1}2	
25740	 w1118;	Df(3R)BSC650/TM6C,	Sb1	cu1	
25944	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF01964}attP2	
26518	 w1118;	Df(3R)BSC666/TM6C,	Sb1	cu1	
26518	 w1118;	Df(3R)BSC666/TM6C,	Sb1	cu1	
26534	 w1118;	Df(3R)BSC682/TM6C,	Sb1	cu1	
26580	 w1118;	Df(3R)BSC728,	P+PBac{w+mC=XP3.RB5}BSC728/TM6C,	Sb1	cu1	
26580	 w1118;	Df(3R)BSC728,	P+PBac{w+mC=XP3.RB5}BSC728/TM6C,	Sb1	cu1	
26724	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF02266}attP2	
26838	 w1118;	Df(3R)BSC740,	P+PBac{w+mC=XP3.RB5}BSC740/TM6C,	Sb1	cu1	
27158	 y1	w*;	P{w+mC=EP}RopG4478/TM3,	Sb1	Ser1	
27237	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF02555}attP2	
27363	 w1118;	Df(3R)BSC791/TM6C,	Sb1	cu1	
27536	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF02687}attP2/TM3,	Sb1	
27722	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF02804}attP2	
27920	 w1118;	Df(3R)BSC847/TM6C,	Sb1	cu1	
28515	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.HM05001}attP2	
28617	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF03032}attP2	
28648	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF03063}attP2	
28697	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF03113}attP2	
28705	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF03122}attP2	
28723	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF03150}attP2/TM3,	Sb1	
28786	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF03214}attP2	
28929	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.HM05140}attP2	
28933	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.HM05144}attP2/TM3,	Sb1	
29322	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF02483}attP2/TM3,	Sb1	
30026	 y1	w1118;	P{w+m*=GawB}GH146	
30620	 y1	w*;	Mi{y+mDint2=MIC}CG31030MI00107/TM3,	Sb1	Ser1	
30819	 w*;	P{w+mW.hs=GawB}Kdm236Y	
31311	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF01258}attP2/TM3,	Ser1	
31322	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF01273}attP2	
31334	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF01291}attP2/TM3,	Ser1	
31348	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF01306}attP2	
31471	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF01245}attP2/TM3,	Sb1	
31484	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.JF01324}attP2	
31803	 w1118;	P{w+mC=EP}CG5916G13766	
31839	 w1118;	P{w+mC=EP}CG14309G19121	
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32040	 P{w+m*=Appl‐GAL4.G1a}1,	y1	w*	
32957	 y1	sc*	v1;	P{y+t7.7	v+t1.8=TRiP.HMS00751}attP2	
32986	 y1	sc*	v1;	P{y+t7.7	v+t1.8=TRiP.HMS00786}attP2	
33615	 y1	v1;	P{y+t7.7	v+t1.8=TRiP.HMS00007}attP2	
33894	 y1	sc*	v1;	P{y+t7.7	v+t1.8=TRiP.HMS00832}attP2	
34391	 y1	sc*	v1;	P{y+t7.7	v+t1.8=TRiP.HMS01385}attP2	
34969	 y1	sc*	v1;	P{y+t7.7	v+t1.8=TRiP.HMS00884}attP2	
36065	 y1	sc*	v1;	P{y+t7.7	v+t1.8=TRiP.GL00423}attP2	
36336	 w*;	CyO,	P{w+mC=2xTb1‐RFP}CyO/T(2;3)apXa	
36337	 FM7c,	P{w+mC=2xTb1‐RFP}FM7c,	sn+/ocotd‐XC86	
45052	 w1118;	P{w+mC=GMR14A10‐GAL4}attP2	
45054	 w1118;	P{w+mC=GMR14B10‐GAL4}attP2	
45224	 w1118;	P{w+mC=GMR34F05‐GAL4}attP2	
45676	 w1118;	P{w+mC=GMR39E11‐GAL4}attP2/TM3,	Sb1	
46021	 w1118;	P{w+mC=GMR51F02‐GAL4}attP2	
46027	 w1118;	P{w+mC=GMR52D08‐GAL4}attP2	
46058	 w1118;	P{w+mC=GMR54F12‐GAL4}attP2	
46066	 w1118;	P{w+mC=GMR55B11‐GAL4}attP2	
46067	 w1118;	P{w+mC=GMR55C06‐GAL4}attP2	
46075	 w1118;	P{w+mC=GMR55G09‐GAL4}attP2	
46373	 w1118;	P{w+mC=GMR57D03‐GAL4}attP2	
46539	 w1118;	P{w+mC=GMR64D08‐GAL4}attP2	
46635	 w1118;	P{w+mC=GMR70F02‐GAL4}attP2	
46649	 w1118;	P{w+mC=GMR71A08‐GAL4}attP2	
46664	 w1118;	P{w+mC=GMR71G07‐GAL4}attP2	
46899	 w1118;	P{w+mC=GMR89H08‐GAL4}attP2/TM3,	Sb1	
46962	 w1118;	P{w+mC=GMR76B09‐GAL4}attP2	
47019	 w1118;	P{w+mC=GMR78E03‐GAL4}attP2	
47245	 w1118;	P{w+mC=GMR94A06‐GAL4}attP2	
47269	 w1118;	P{w+mC=GMR95A01‐GAL4}attP2	
47634	 w1118;	P{w+mC=GMR52A01‐GAL4}attP2	
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Table	B.2	
	
Overview	of	Exelixis	deficiency	screen	in	a	sda	background	
	
Exelixis	Number	 Stock	Number	 %	paralyzed	 Fold	change	 #	tested	
Df(3R)Exel6140		 7619	 5.4	 0.9	 74	
Df(3R)Exel6141		 7620	 0.0	 0.0	 60	
Df(3R)Exel6142		 7621	 0.0	 0.0	 60	
Df(3R)Exel6143		 7622	 0.0	 0.0	 68	
Df(3R)Exel6144		 7623	 13.3	 2.2	 60	
Df(3R)Exel6145		 7624	 11.7	 1.9	 60	
Df(3R)Exel6146		 7625	 8.0	 1.3	 50	
Df(3R)Exel6147		 7626	 7.7	 1.2	 65	
Df(3R)Exel6148		 7627	 0.0	 0.0	 95	
Df(3R)Exel6149		 7628	 0.0	 0.0	 67	
Df(3R)Exel6150		 7629	 23.1	 3.7	 52	
Df(3R)Exel6151		 7630	 63.3	 10.2	 120	
Df(3R)Exel6152		 7631	 0.0	 0.0	 60	
Df(3R)Exel6153		 7632	 0.0	 0.0	 82	
Df(3R)Exel6154		 7633	 50.8	 8.2	 59	
Df(3R)Exel6155		 7634	 10.0	 1.6	 60	
Df(3R)Exel6156		 7635	 1.7	 0.3	 60	
Df(3R)Exel6157		 7636	 11.7	 1.9	 60	
Df(3R)Exel6158		 7637	 12.0	 1.9	 75	
Df(3R)Exel6159		 7638	 15.8	 2.5	 76	
Df(3R)Exel6160		 7639	 11.7	 1.9	 60	
Df(3R)Exel6161		 7640	 23.9	 3.9	 71	
Df(3R)Exel6162		 7641	 1.6	 0.3	 64	
Df(3R)Exel6163		 7642	 5.2	 0.8	 58	
Df(3R)Exel6164		 7643	 8.3	 1.3	 60	
Df(3R)Exel6165		 7644	 60.0	 9.7	 60	
Df(3R)Exel6166		 7645	 3.3	 0.5	 60	
Df(3R)Exel6167		 7646	 20.0	 3.2	 60	
Df(3R)Exel6168		 7647	 0.0	 0.0	 72	
Df(3R)Exel6169		 7648	 0.0	 0.0	 60	
Df(3R)Exel6170		 7649	 1.7	 0.3	 60	
Df(3R)Exel6171		 7650	 0.0	 0.0	 75	
Df(3R)Exel6172		 7651	 20.0	 3.2	 60	
Df(3R)Exel6173		 7652	 3.2	 0.5	 62	
Df(3R)Exel6174		 7653	 1.4	 0.2	 69	
Df(3R)Exel6176		 7655	 0.0	 0.0	 67	
Df(3R)Exel6178		 7657	 21.7	 3.5	 60	
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Exelixis	Number	 Stock	Number	 %	paralyzed	 Fold	change	 #	tested	
Df(3R)Exel6179		 7658	 2.3	 0.4	 88	
Df(3R)Exel6180		 7659	 0.0	 0.0	 66	
Df(3R)Exel6181		 7660	 20.0	 3.2	 60	
Df(3R)Exel6182		 7661	 0.0	 0.0	 57	
Df(3R)Exel6184		 7663	 0.0	 0.0	 60	
Df(3R)Exel6185		 7664	 0.0	 0.0	 60	
Df(3R)Exel6186		 7665	 0.0	 0.0	 60	
Df(3R)Exel6187		 7666	 1.0	 0.2	 98	
Df(3R)Exel6188		 7667	 0.0	 0.0	 60	
Df(3R)Exel6189		 7668	 14.9	 2.4	 67	
Df(3R)Exel6190		 7669	 5.5	 0.9	 55	
Df(3R)Exel6191		 7670	 9.1	 1.5	 77	
Df(3R)Exel6192		 7671	 0.0	 0.0	 60	
Df(3R)Exel6193		 7672	 6.7	 1.1	 60	
Df(3R)Exel6194		 7673	 1.7	 0.3	 60	
Df(3R)Exel6195		 7674	 0.0	 0.0	 69	
Df(3R)Exel6196		 7675	 43.3	 7.0	 60	
Df(3R)Exel6197		 7676	 3.6	 0.6	 56	
Df(3R)Exel6198		 7677	 0.0	 0.0	 60	
Df(3R)Exel6199		 7678	 0.0	 0.0	 60	
Df(3R)Exel6200		 7679	 0.0	 0.0	 60	
Df(3R)Exel6201		 7680	 0.0	 0.0	 54	
Df(3R)Exel6202		 7681	 5.0	 0.8	 60	
Df(3R)Exel6203		 7682	 18.3	 3.0	 60	
Df(3R)Exel6204		 7683	 8.3	 1.3	 60	
Df(3R)Exel6205		 7684	 33.3	 5.4	 51	
Df(3R)Exel6206		 7685	 9.4	 1.5	 64	
Df(3R)Exel6208		 7686	 15.0	 2.4	 60	
Df(3R)Exel6209		 7687	 0.0	 0.0	 60	
Df(3R)Exel6210		 7688	 0.0	 0.0	 65	
Df(3R)Exel6211		 7689	 3.3	 0.5	 60	
Df(3R)Exel6212		 7690	 5.1	 0.8	 59	
Df(3R)Exel6213		 7691	 0.0	 0.0	 92	
Df(3R)Exel6214		 7692	 0.0	 0.0	 19	
Df(3R)Exel6215		 7693	 0.0	 0.0	 60	
Df(3R)Exel6216		 7694	 0.0	 0.0	 82	
Df(3R)Exel6217		 7695	 11.7	 1.9	 60	
Df(3R)Exel6218		 7696	 1.5	 0.2	 65	
Df(3R)Exel6259		 7726	 0.0	 0.0	 65	
Df(3R)Exel6263		 7730	 0.0	 0.0	 1	
Df(3R)Exel6264		 7731	 0.0	 0.0	 60	
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Exelixis	Number	 Stock	Number	 %	paralyzed	 Fold	change	 #	tested	
Df(3R)Exel6265		 7732	 11.7	 1.9	 60	
Df(3R)Exel6267		 7734	 3.3	 0.5	 60	
Df(3R)Exel6269		 7736	 0.0	 0.0	 60	
Df(3R)Exel6270		 7737	 71.7	 11.6	 60	
Df(3R)Exel6273		 7740	 0.0	 0.0	 53	
Df(3R)Exel6274		 7741	 2.9	 0.5	 69	
Df(3R)Exel6275		 7742	 3.3	 0.5	 60	
Df(3R)Exel6276		 7743	 3.4	 0.5	 59	
Df(3R)Exel6280		 7746	 0.0	 0.0	 60	
Df(3R)Exel6288		 7752	 0.0	 0.0	 60	
Df(3R)Exel9020		 7917	 3.4	 0.5	 59	
Df(3R)Exel8194		 7918	 18.3	 3.0	 60	
Df(3R)Exel7379		 7919	 36.5	 5.9	 63	
Df(3R)Exel7315		 7931	 15.5	 2.5	 58	
Df(3R)Exel7317		 7932	 40.4	 6.5	 52	
Df(3R)Exel7357		 7948	 0.0	 0.0	 60	
Df(3R)Exel9029		 7951	 0.0	 0.0	 60	
Df(3R)Exel7283		 7952	 0.0	 0.0	 78	
Df(3R)Exel7284		 7953	 3.3	 0.5	 60	
Df(3R)Exel8143		 7954	 1.7	 0.3	 60	
Df(3R)Exel9036		 7955	 16.7	 2.7	 60	
Df(3R)Exel7305		 7956	 35.0	 5.6	 60	
Df(3R)Exel7306		 7957	 1.7	 0.3	 60	
Df(3R)Exel8152		 7958	 5.0	 0.8	 60	
Df(3R)Exel7308		 7959	 0.0	 0.0	 60	
Df(3R)Exel7309		 7960	 0.0	 0.0	 60	
Df(3R)Exel8154		 7961	 13.3	 2.2	 60	
Df(3R)Exel9018		 7962	 21.7	 3.5	 60	
Df(3R)Exel8153		 7963	 5.0	 0.8	 60	
Df(3R)Exel9019		 7964	 6.7	 1.1	 60	
Df(3R)Exel7310		 7965	 1.7	 0.3	 60	
Df(3R)Exel7312		 7966	 33.3	 5.4	 60	
Df(3R)Exel8155		 7967	 0.0	 0.0	 60	
Df(3R)Exel7313		 7968	 10.0	 1.6	 80	
Df(3R)Exel7314		 7969	 0.0	 0.0	 53	
Df(3R)Exel7316		 7970	 5.4	 0.9	 74	
Df(3R)Exel7318		 7972	 5.0	 0.8	 60	
Df(3R)Exel8157		 7973	 32.4	 5.2	 71	
Df(3R)Exel8158		 7974	 11.7	 1.9	 60	
Df(3R)Exel7320		 7975	 13.2	 2.1	 53	
Df(3R)Exel8159		 7976	 0.0	 0.0	 52	
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Exelixis	Number	 Stock	Number	 %	paralyzed	 Fold	change	 #	tested	
Df(3R)Exel7321		 7977	 16.7	 2.7	 60	
Df(3R)Exel7326		 7980	 0.0	 0.0	 60	
Df(3R)Exel8162		 7981	 2.8	 0.4	 72	
Df(3R)Exel7327		 7982	 5.7	 0.9	 70	
Df(3R)Exel7329		 7984	 0.0	 0.0	 57	
Df(3R)Exel7330		 7985	 3.3	 0.5	 60	
Df(3R)Exel8163		 7987	 1.6	 0.3	 64	
Df(3R)Exel8165		 7988	 0.0	 0.0	 60	
Df(3R)Exel9030		 7989	 28.3	 4.6	 60	
Df(3R)Exel9012		 7990	 0.0	 0.0	 60	
Df(3R)Exel9013		 7991	 23.3	 3.8	 60	
Df(3R)Exel9014		 7992	 10.0	 1.6	 70	
Df(3R)Exel8178		 7993	 3.3	 0.5	 60	
Df(3R)Exel9056		 7994	 3.0	 0.5	 99	
Df(3R)Exel9025		 7995	 23.3	 3.8	 60	
Df(3R)Exel7378		 7997	 1.5	 0.2	 67	
	
 94 
	
	
	
	
	
	
	
	
	
Table	B.3	
Bang‐sensitivity	in	parabss1	crossed	to	seizure‐enhancing	Exelixis	deficiencies	
	
Exelixis	
Deficiency	
Stock	
Number	
%	
Paralyzed	
Fold	
change	 #	tested	
Df(3R)Exel6150		 7629	 40.0	 1.0	 60	
Df(3R)Exel6151		 7630	 95.9	 2.5	 73	
Df(3R)Exel6154		 7633	 69.8	 1.8	 53	
Df(3R)Exel6161		 7640	 68.3	 1.8	 60	
Df(3R)Exel6165		 7644	 38.7	 1.0	 75	
Df(3R)Exel6178		 7657	 71.2	 1.8	 73	
Df(3R)Exel6196		 7675	 45.2	 1.2	 73	
Df(3R)Exel6270		 7737	 76.7	 2.0	 60	
Df(3R)Exel7305		 7956	 95.0	 2.4	 60	
Df(3R)Exel7317		 7932	 96.2	 2.5	 52	
Df(3R)Exel7328		 7983	 98.5	 2.5	 68	
Df(3R)Exel7379		 7919	 85.0	 2.2	 60	
Df(3R)Exel8157		 7973	 100.0	 2.6	 58	
Df(3R)Exel9013		 7991	 44.9	 1.1	 49	
Df(3R)Exel9025		 7995	 81.1	 2.1	 53	
control	 		 		 		 		
w1118	 5905	 39.0	 1.0	 105	
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Table	B.4	
Bang‐sensitivity	in	eas	crossed	to	seizure‐enhancing	Exelixis	deficiencies	
	
Exelixis	
Deficiency	 Stock	Number	
%	
paralyzed	 Total	N	
Df(3R)Exel6150	 7629	 0	 58	
Df(3R)Exel6151	 7630	 11.5	 52	
Df(3R)Exel6154	 7633	 0.0	 80	
Df(3R)Exel6161	 7640	 0.0	 87	
Df(3R)Exel6165	 7644	 0.0	 67	
Df(3R)Exel6178	 7657	 0.0	 76	
Df(3R)Exel6196	 7675	 0.0	 53	
Df(3R)Exel6270	 7737	 2.2	 89	
Df(3R)Exel7305	 7956	 0.0	 64	
Df(3R)Exel7317	 7932	 0.0	 63	
Df(3R)Exel7328	 7983	 0.0	 61	
Df(3R)Exel7379	 7919	 0.0	 59	
Df(3R)Exel8157	 7973	 0.0	 62	
Df(3R)Exel9013	 7991	 0.0	 51	
Df(3R)Exel9025	 7995	 0.0	 53	
control	 		 		 		
w1118	 5905	 0	 71	
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Table	B.5	
Bang‐sensitivity	testing	of	sda	crossed	to	deficiencies	overlapping	seizure‐
enhancing	Exelixis	deficiencies		
	
Stock	
Number	 Genotype	
%	
paralyzed	
Fold	
change	 #	of	flies	tested	
7661	 Df(3R)Exel6182	 0.0	 0.0	 60	
7731	 	Df(3R)Exel6264	 2.5	 0.2	 40	
7969	 Df(3R)Exel7314	 10.4	 0.9	 48	
8968	 Df(3R)ED5516	 2.5	 0.2	 40	
9086	 Df(3R)ED5591	 16.7	 1.5	 60	
9206	 Df(3R)ED5573	 16.7	 1.5	 24	
9225	 Df(3R)ED5301	 5.0	 0.4	 60	
9227	 Df(3R)ED5428	 20.5	 1.8	 44	
9338	 Df(3R)ED5296	 7.7	 0.7	 26	
9482	 Df(3R)ED10642	 33.3	 3.0	 60	
9699	 Df(3R)BSC222	 27.4	 2.4	 62	
24976	 Df(3R)BSC472	 0.0	 0.0	 60	
24981	 Df(3R)BSC477	 13.9	 1.2	 36	
24994	 Df(3R)BSC490	 13.8	 1.2	 29	
25006	 Df(3R)BSC502	 8.9	 0.8	 45	
25013	 Df(3R)BSC509	 41.7	 3.7	 60	
25057	 Df(3R)BSC529	 0.0	 0.0	 60	
25126	 Df(3R)BSC568	 36.7	 3.3	 60	
25740	 Df(3R)BSC650	 0.0	 0.0	 86	
26534	 Df(3R)BSC682	 6.7	 0.6	 60	
26580	 Df(3R)BSC728	 3.3	 0.3	 60	
26838	 Df(3R)BSC740	 9.4	 0.8	 53	
27363	 Df(3R)BSC791	 20.0	 1.8	 60	
27920	 Df(3R)BSC847	 1.7	 0.1	 60	
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Figure	 B.1	 	 Bang‐sensitivity	 testing	 of	 sda	 crossed	 to	 deficiencies	 overlapping	
seizure‐enhancing	 Exelixis	 deficiencies.	 	 These	 deficiencies	 overlap	 with	 the	
Exelixis	deficiencies	found	to	be	enhancers	in	the	screen.		Control	is	sda/+.		N≥24	
for	each	deficiency.	
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Table	B.6	
Bang‐sensitivity	of	transposon	insertion	alleles	crossed	to	slamdance	
	
Gene	 Associated	Exel	Df	 %	Paralyzed	 Fold	Difference	 Number	Tested	
w1118	 5905	 6.1	 1	 180	
Akt	 7983	 35.0	 5.7	 20	
CG10324	 7737	 0.0	 0.0	 34	
CG11140	 7675	 63.8	 10.4	 80	
CG14309	 7657	 16.3	 2.7	 80	
CG18005	 7630	 15.0	 2.5	 60	
CG31140	 7675	 18.3	 3.0	 60	
CG5903	 7983	 0.0	 0.0	 20	
CG5916	 7983	 3.8	 0.6	 80	
CG6574	 7956	 1.7	 0.3	 60	
CtBP	 7973	 11.3	 1.8	 80	
Fas1	 7737	 0.0	 0.0	 60	
Glut4ef	 7633	 17.5	 2.9	 80	
GycBeta	 7919	 36.7	 6.0	 60	
Hug	 7932	 11.7	 1.9	 60	
kdm2	 7630	 13.3	 2.2	 60	
Koko	 7657	 10.0	 1.6	 80	
Mcm5	 7638	 11.7	 1.9	 60	
nonA‐1	 7737	 11.4	 1.9	 70	
Pros	 7962	 0.0	 0.0	 60	
Pum	 7630	 8.8	 1.4	 80	
Repo	 7657	 1.0	 0.2	 100	
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Table	B.7	
Bang‐sensitivity	of	RNAi	lines	crossed	to	elav‐GAL4;	sda	
	
Target	Gene	
Associated	Exel	
Stock	
%	
paralyzed	
Fold	
difference	 #	tested	
control	 2.5	 1	 80	
AdoR	 7692	 12.5	 5	 80	
Art1	 7956	 7.0	 2.8	 100	
ATPsyngamma	 7995	 1.4	 0.6	 69	
ccty	 7737	 0.0	 0	 17	
CG18549	 7932	 0.0	 0	 100	
CG18616	 7932	 7.7	 3.1	 13	
CG3747	 7730	 5.0	 2	 100	
CG42342	 7737	 15.0	 6	 80	
CG4596	 7956	 6.3	 2.5	 80	
CG9467	 7633	 10.0	 4	 80	
CtBP	 7973	 0.0	 0	 80	
fbx011	 7633	 1.3	 0.5	 80	
fer2	 7983	 16.3	 6.5	 80	
GycBeta	 7919	 13.8	 5.5	 80	
hug	 7932	 4.0	 1.6	 100	
npf	 7737	 5.0	 2	 100	
sima	 7692	 31.3	 12.5	 80	
Tsp86D	 7956	 10.0	 4	 80	
yata	 7995	 7.5	 3	 80	
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Figure	 B.2	 	 Map	 of	 deletions	 and	 alleles	 within	 Exel6263	 tested	 for	 synthetic	
lethality	with	sda.	 	Orange	boxes	represent	genotypes	that	resulted	 in	synthetic	
lethality.		Blue	boxes	represent	viable	crosses.	
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Table	B.8	
Candidate	genes	within	Exel6263	that	may	cause	partial	synthetic	lethality	with	
sda	
	
Candidate	
Genes		 Function	 Expression	
CD98hc	 cation	binding,	leucine	import	 high	in	most	tissues	
CG10435	 unknown		 high	in	most	tissues	
CG11052	 acylphosphatase	activity	 high	in	testis	
CG14463	 phosphatidylinositol	N‐
acetylglucosaminyltransferase	
activity	
low	in	most	tissues	
CG2698	 unknown		 moderate	in	nervous	system	and	other	
tissues	
CG2767	 alcohol	dehydrogenase	 low	in	nervous	system,	high	in	eye/crop	
CG2781	 fatty	acid	synthesis	 high	in	gut	and	head	
CG3223	 unknown		 moderate	in	most	tissues	
CG42550	 unknown		 unknown	
Os‐C	 pheremone	binding	 high	in	head	
Pbp95	 DNA	binding,	lateral	inhibition	 high	in	ovaries,	low	in	most	tissues	
Sfp84E	 Reproduction	 unknown	
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Table	B.9	
Genes	within	Exel6214	tested	for	lethality	in	combination	with	sda	
	
Stock	Description	 Function	 Viable	with	sda?
Exel6214	 semilethal	
Adenosine	receptor	(AdoR) Synaptic	transmission viable	
similar		(sima)	 Transcription	regulation viable	
CG31030	 ATP	hydrolysis viable	
 103 
	
Table	B.10	
Summary	of	all	deficiencies	and	alleles	tested	by	crossing	to	sda	
	
Exelixis	Deficiency	 Gene Type Stock	Number	 Fold	Change
Df(3R)Exel6151	 7630 10.4
Df(3R)ED5296 Deficiency 9338 1.3
Kdm2	 P‐element 30819 2.2
CG18995 P‐element 15965 2.5
pum	 P‐element 21042 3.3
pum	 P‐element 11544 3.7
Df(3R)Exel6154		 		 7633 8.3
Teh1	 P‐element 13221 0.0
Glut4ef P‐element 16364 2.9
CG9467 RNAi 26724 4.0
fbx011 RNAi 31484 0.5
Df(3R)Exel6178		 		 7657 3.6
Df(3R)BSC650 Deficiency 25740 0.0
Df(3R)BSC682 Deficiency 26534 1.1
Df(3R)BSC509 Deficiency 25013 6.8
repo	 P‐element 11604 0.2
koko	 P‐element 21214 1.6
CG14309 P‐element 31839 2.7
Df(3R)Exel6196		 		 7675 7.1
Df(3R)Exel9014 Deficiency 7992 1.6
CG31140 P‐element 23750 3.0
CG11140 P‐element 13427 10.5
Df(3R)Exel6270		 		 7737 11.7
Df(3R)BSC472 Deficiency 24976 0.0
Df(3R)ED10642 Deficiency 9482 5.5
Fas1	 P‐element 16029 0.0
npf	RNAi RNAi 27237 0.8
nonA‐1 P‐element 16690 1.9
CG10324 P‐element 19012 0.0
CG42342 RNAi 28628 6.0
ccty	 P‐element 34969 0.0
Df(3R)Exel7379		 		 7919 6.0
GycB	 P‐element 15221 6.0
GycB	 RNAi 28786 5.5
Df(3R)Exel7317		 7932 6.6
Df(3R)BSC847 Deficiency 27920 0.3
Df(3R)ED5573 Deficiency 9206 2.7
hug	 RNAi 28705 1.6
hug	 P‐element 23491 1.9
CG18616 RNAi 32957 3.1
CG18549 RNAi 34391 0.0
Df(3R)Exel7305		 		 7956 5.7
 104 
Df(3R)BSC529 Deficiency 25057 0.0
Df(3R)BSC568 Deficiency 25126 6.0
Art1	 RNAi 31348 1.1
CG6574 P‐element 17837 0.3
Tsp86D RNAi 28515 4.0
CG4596 RNAi 28617 2.5
Df(3R)Exel7328		 		 7983 3.8
Df(3R)Exel7327 Deficiency 7982 0.9
Df(3R)BSC728 Deficiency 26580 0.3
Akt	 P‐element 11627 5.7
CG5903 P‐element 20714 0.0
CG5916 P‐element 31803 0.6
fer2	 RNAi 28697 6.5
Df(3R)Exel9025		 		 7995 3.8
ATPsyngamma RNAi 28723 0.6
		 yata	 RNAi 32986 3.0
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Table	B.11	
Exelixis	deficiency	enhancers	of	sda	with	no	identified	enhancer	genes	
	
Exelixis	
Deficiency	 Gene	 Type	
Stock	
Number	 Fold	Change	
Df(3R)Exel6150		 7629	 3.8	
		 Df(3R)BSC477	 Deficiency	 24981	 2.3	
Df(3R)Exel6161		 		 		 7640	 3.9	
Deficiency	 8968	 0.4	
Deficiency	 7743	 0.6	
Df(3R)Exel6165		 		 		 7644	 9.8	
Df(3R)BSC740	 Deficiency	 26838	 1.5	
		 Df(3R)ED5591	 Deficiency	 9086	 2.7	
Df(3R)Exel8157		 		 7973	 5.3	
CtBP	 Transposon	 11590	 1.6	
CtBP	 RNAi	 31334	 0.0	
Df(3R)Exel9013		 		 		 7991	 3.8	
Df(3R)BSC490	 Deficiency	 24994	 2.3	
		 WASp	 Transposon	 25955	 0.0	
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APPENDIX C 
SUPPLEMENTARY MATERIAL FOR CHAPTER 3 
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Figure	C.1		Double	staining	of	pum	and	synaptic	marker	brp	in	adult	brains.		
Confocal	images	were	taken	of	the	central	brain	region.		Expression	of	pum	is	
separate	from	the	neuropil	labeled	by	brp.		Scale	bars	are	100	µm.	
αpum              αbrp       merge 
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Figure	 C.2	 	 Double	 staining	 of	 pum	 and	 repo,	 a	 glial	 marker,	 in	 adult	 brains.		
Confocal	image	were	taken	of	the	central	brain	region.		Cells	positive	for	repo	do	
not	overlap	those	labeled	for	pum.		Scale	bars,	100	µm.	
	
	
αpum             αrepo      merge 
 109 
 
 
 
 
 
 
 
 
 
Figure	 C.3	 	 Double	 staining	 of	 pum	 and	 nc82	 (brp),	 a	 synaptic	 marker,	 after	
targeted	knockdown	of	pum	by	several	GAL4	lines	including	elav	(panneuronal),	
OK6	(motor	neurons),	VGlut	(glutamatergic	neurons),	Cha	(cholinergic	neurons),	
and	Gad2B	(GABAergic	neurons).		Scale	bar,	100	µm.	
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Figure	C.4		Knockdown	of	pumilio	using	RNAi	targeted	to	all	neurons	(elav)	in	the	
larval	brain.	 	Confocal	 images	of	 third	 instar	 larvae	brains	stained	with	pumilio	
and	elav.		Scale	bar,	50	μm.	
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Table	C.1	
Behavior	testing	after	knockdown	of	pumilio	in	various	cell	types	by	RNAi	
	
Genotype	 Targeted	Cell	Type	
#	
paralyzed N	
%	
seized	
Fold	
change	
parabss1/+	;	pum‐RNAi/+	 control	 72	 155	 46.5	 1.0	
	
parabss1/elav‐GAL4;	pum‐
RNAi/+	 panneuronal	 50	 50	 100.0	 2.2	
	
parabss1/appl	–GAL4;	
pum‐RNAi/+	 panneuronal	 88	 96	 91.7	 2.0	
	
parabss1/+	;	pum‐
RNAi/tdc2	 octopaminergic	neurons	 16	 21	 76.2	 1.6	
	
parabss1/vglut	–GAL4;	
pum‐RNAi/+	 glutamatergic	neurons	 14	 28	 50.0	 1.1	
	
parabss1/+	;	VaCHT‐
GAL4/pum‐RNAi	 cholinergic	neurons	 20	 21	 95.2	 2.1	
	
parabss1/+	;	cha‐
GAL4/pum‐RNAi	 cholinergic	neurons	 65	 71	 91.5	 2.0	
	
parabss1/+	;	slit‐GAL4/+;	
pum‐RNAi/+	 glia	 11	 33	 33.3	 0.7	
	
parabss1/+		;	repo‐
GAL4/+;	pum‐RNAi/+	 glia	 22	 40	 55.0	 1.2	
	
parabss1/+	;	gad1‐
GAL4/pum‐RNAi	 GABA‐ergic	neurons	 23	 37	 62.2	 1.3	
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Table	C.2	
Behavior	testing	after	knockdown	of	Pum	by	RNAi	in	a	slamdance	background	
Genotype	 Target	 N	
#	
Paralyzed	
%	
Paralyzed	
Fold	
Change	
pum‐RNAi/+;	sda/+	 control	 80	 4	 5.0	 1.0	
	
elav‐GAL4,	pum‐RNAi/+;	
sda/+	 panneural	 80	 65	 81.3	 16.3	
	
Gad2B/pum‐RNAi;	sda/+	 GABAergic	neurons	 80	 63	 78.8	 15.8	
pum‐RNAi/VAChT‐GAL4;	
sda/+	 cholinergic	neurons	 119	 49	 41.2	 8.2	
	
pum‐RNAi/Tdc2‐GAL4;	
sda/+	
octopaminergic	
neurons	 80	 23	 28.8	 5.8	
	
Vglut‐GAL4/+;	pum‐
RNAi/+;	sda/+	
glutamatergic	
neurons	 80	 17	 21.3	 4.3	
	
pum‐RNAi/+;	sda/slit‐
GAL4	 glia	 80	 10	 12.5	 2.5	
	
pum‐RNAi/cha‐GAL4;	
sda/+	 cholinergic	neurons	 65	 7	 10.8	 2.2	
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Table	C.3	
Seizure	threshold	in	flies	with	neuron‐targeted	pum	knockdown	
	
Genotype	 Seizure	threshold	±	SE	(V)	
Number	
tested	
	
parabss1/+	;	pum‐RNAi/+	 10.58	±	1.22	 12	
	
parabss1,	elav‐GAL4/+	;	pum‐RNAi/+	
	
7.56	±	0.53	
	
9	
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Table	C.4	
Effects	of	pumilio	overexpression	on	larval	survival	
	
Age	of	larvae	at	time	
of	heat	shock	(days)	
Life	cycle	
stage	
%	survival	with	heat	
shock	
%	survival	without	
heat	shock	
1	 First	Instar	 100.0	 100.0	
2	 96.9	 97.4	
3	 Second	Instar	 100.0	 100.0	
4	 100.0	 100.0	
5	 Third	Instar	 100.0	 100.0	
6	 97.4	 98.2	
7	
Wandering	
Third	Instar	 77.4	 100.0	
8	 Pupa	 64.7	 100.0	
10	 		 95.8	 100.0	
	
 
 
